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Abstract 
The ability of fluoroquinolones (ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, 
norfloxacin and ofloxacin), (3-lactams (cefotaxime, ceftazidime, ceftriaxone and 
meropenem) and aminoglycosides (amikacin, gentamicin and netilmicin) to select 
resistant mutants of Salmonella sp, Escherichia coli and Pseudomo门as aeruginosa 
and the rate at which these organisms developed resistance to the tested antibiotics 
were investigated. 
Forty strains each of salmonellae and E coli and 30 strains of P aeruginosa were 
subjected to daily subculture in broth containing increasing two-fold dilutions of an 
antibiotic. The subcultures were tested daily for susceptibility to antibiotics by an agar 
dilution method using breakpoint concentrations as recommended by the National 
Committee for Clinical Laboratory Standards (2001). 
The fluoroquinolones tested had different potentials in selecting for 
fluoroquinolone-resistant Salmonella sp, E coli and P aeruginosa. Gemifloxacin and 
moxifloxacin had the highest potential to select fluoroquinolone-resistant strains of 
Salmonella and E co//while levofloxacin had the lowest potential. Moxifloxacin had the 
highest potential to select resistant strains of P aeruginosa. Resistance to gemifloxacin 
developed most readily when the three organisms were passaged in any of the six 
fluoroquinolones while resistance to ciprofloxacin or levofloxacin developed least 
readily. 
The potential of ceftazidime and ceftriaxone to select resistant salmonellae was similar 
and was higher than that of cefotaxime. In contrast, the potential of ceftriaxone to 
select resistant E coli was lowest. Resistance to ceftazidime of both organisms 
developed more readily in the presence of any of the three cephalosporins tested. Of 
the two p-lactams tested for P aeruginosa, meropenem more readily selected for 
resistance than ceftazidime. 
Netilmicin had the highest potential to select aminoglycoside-resistant salmonellae but 
the lowest potential to select aminoglycoside-resistant E coli. All three aminoglycosides 
had similar potential to select for resistant P aeruginosa strains. 
Slimilar propotions of Salmonella ap and E coli strains but more P aeruginosa strains 
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Chapter 1 Introduction 
A. Antibiotic use and resistance 
Antibiotics are perhaps the most frequently prescribed group of drugs in both the 
hospital and community setting. They have been used for prophylaxis as well as 
treatment of bacterial infections. The volume of use is huge. Bacteria that are 
naturally sensitive to antibiotics subsequently become resistant through various 
means under the selective pressure of antibiotics (Dunlop et a!., 1998). They not 
only become resistant to single antibiotics, they may become multiple-resistant, ie, 
simultaneously resistant to two or more antibiotics. Clinicians often face the 
daunting task of choosing a suitable and effective drug to treat their patients. 
In the past, pharmaceutical companies aggressively research into the 
development of new drugs that can evade the resistance mechanisms of bacteria, 
but they are now producing less new antibiotics. This is because the process of 
antibiotic production is extremely slow and costly. According to an article in the 
May 2002 issue of Medical Tribune, the cost of development of new drugs 
(US$231 million to develop one drug 10 years ago as compared to US$803 
million today), the period of time taken to develop a drug (10 to 15 years) and the 
short patent life (20 years) are major disincentives to drug development (Yip, 
2002). Besides, bacteria very quickly develop resistance to an antibiotic once it is 
introduced into clinical use. The fact that the rate by which new drugs appear on 
the market can not match that of the emergence of resistant organisms is 
generally recognized. Thus, it is important to prevent the development and spread 
of resistance rather than to develop newer drugs to combat resistant bacteria. 
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The high level of antibiotic resistance in Hong Kong has been noted by various 
workers several years ago (Ling & Cheng, 1995; K a m et al., 1995; Ling et al., 
1996; Lyon et al., 1996; Tint et al., 1996; Ho et al., 1999). This poses a serious 
problem for clinicians who frequently have to prescribe antibiotics to their patients 
blindly as they may encounter treatment failure. Misuse and overuse of antibiotics 
are the culprit of the problem of antibiotic resistance. It is only through choosing 
the right antibiotic that the chance of selecting resistant organisms be reduced. 
B. Selection of resistant strains by antibiotics 
The susceptibility to different antibiotics of individual organisms isolated from 
patient specimens is tested in routine practice. They have shown in their previous 
study that it is more important to determine the resistance induction and selection 
potential of a drug (Chan etal., 1999). This (Chan et al., 1999) and our 
unpublished observations showed that different p-lactam antibiotics with 
apparently similar activity induce and select resistant strains at different rates and 
are dependent on the resistance mechanisms of bacteria. 
There are various studies done by other workers on the effects of antibiotics on 
the emergence of bacterial resistance. Ciprofloxacin and ofloxacin have been 
shown to select resistant mutants more readily than sparfloxacin and levofloxacin 
(Piddock & Jin, 1992; Klugman, Capper & Bryskier, 1996). Moxifloxacin was 
shown to select resistant strains of Pseudomonas aeruginosa but not 
Streptococcus pneumoniae (MacGowan et al; 2003). Nagai and colleagues (2000) 
found that most strains of S pneumoniae tested developed resistance in the 
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presence of ciprofloxacin and the least number of strains developed resistance in 
the presence of clinafloxacin. Gilbert et a! (2001) exposed both Gram-positive and 
Gram-negative bacteria to ciprofloxacin, levofloxacin and trovafloxacin and found 
that all strains developed resistance albeit at different frequencies for each of the 
drugs tested. Trovafloxacin selected Staphyloccus aureus and Serratia 
marcescens at a higher frequency than ciprofloxacin while ciprofloxacin selected 
Enterobacter cloacae at the highest frequency when compared to levofloxacin 
and trovafloxacin. By growing S aureus in antibiotic-containing broth, Schmitz et 
al (2000) demonstrated a correlation between methicillin-resistance and 
resistance to ciprofloxacin, rifampin and mupirocin and attributed the differences 
in resistance rates to spontaneous mutation rates. Development of resistance to 
fluoroquinolones has also been demonstrated in anaerobes such as Bacteroides 
fragilis and B thetaiotamicron following exposure to different fluoroquinolones 
(Peterson et al, 1999; Ross et al, 2001). 
Resistant strains of S pneumoniae developed in the presence of sub-inhibitory 
concentrations of various p-lactam antibiotics (Carsenti-Etesse et al., 1995). 
However, Pankuch et al (1998) could only detect one out of six pneumococci 
tested to have amoxicillin MICs increased following exposure to the same drug. 
Thorburn and colleagues (1998) also found that penicillin-susceptible 
pneumococci could be rapidly killed if exposed to cefpodoxime, cefuroxime, 
amoxicillin or amoxicillin-clavulanate at the maximum serum concentration after 
an oral dose of the drugs but penicillin-resistant pneumococci had their 
cefopodoxime and cefuroxime MICs decreased following exposure to maximum 
serum concentration of the respective drug. 
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Enterococcus faecium strains resistant to a new streptogramin could be selected 
by the drug (Millichap et al., 1996). In contrast, Puntorieri et al. (1999) were 
unable to select enterococcal mutants resistant to glycopeptides after exposure to 
these drugs. Sahm et al. (2000) also found that S pneumoniae strains resistant to 
4 mg/l of ciprofloxacin remain uncommon after 10 years of use of the drug. 
Development of resistance has also been studied in Haemophilus 
influenzae, Stenotrophomonas maltophilia, Helicobacter pylori Mycoplasma 
pneumoniae (Soberg et al., 1998; Clark et al., 2002; Pereyre et a/.,2004; Ba et al., 
2004). These organisms were exposed to a variety of drugs such as the newer 
macrolides, fluoroquinolones or metronidazole and resistance developed to 
various extents in these organisms. Thus, antibiotics have different potentials in 
selecting for resistance in different organisms and that antimicrobial potency is not 
the only factor that has to be considered in controlling the development and 
spread of resistance. 
Our unpublished observation showed that while resistance to certain antibiotics in 
our hospital became more prevalent over the years, resistance to other antibiotics 
became less common or the prevalence remained almost unchanged. This 
illustrates the fact that w e cannot rely solely on antimicrobial susceptibility as the 
parameter in the surveillance of antimicrobial resistance to tackle the problem of 
resistance. 
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Since antibiotic resistance is a worldwide problem, various measures have been 
proposed to control the spread of resistant bacteria. S o m e of these include 
controls on or reductions of antibiotic use (Anonymous, 1995) and cycling of 
different antibiotics (Swartz, 1994). However, little success has been achieved. 
Knowledge on the most appropriate treatment in limiting the development of 
resistance is also not available. This is because development of resistance is a 
complex issue that involves the interaction of host and pathogen, population 
dynamics of resistant and sensitive strains, mechanisms of resistance, 
pharmacodynamics and pharmacokinetics of drug-pathogen interactions, and 
cost-effectiveness of different antibiotic regimens. Dunlop et a!. (1998) have 
shown that there are major differences between the types of antibiotics and their 
effect on the occurrence of resistance. The ultimate solution therefore is to devise 
an optimal antibiotic policy that can prolong the time when resistant bacteria 
become a fixed and predominant fraction of all strains of a given species 
(Bonhoeffer, Lipsitch & Levin, 1997). This requires the study of the potential of 
different administration and dosing intervals of antimicrobial agents to select for 
resistance. N e w mechanisms mediating resistance to antimicrobial agents have 
arisen in recent years (Hall & Stokes, 1993; Verdet et a/•，2000). It is therefore 
also important to study bacterial defense mechanisms and the effects of 
successive use of different antimicrobial agents on their development. 
C. Fluoroquinolones 
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Fluoroquinolones are a group of antimicrobial agents that were derived from the 
quinolones of which nalidixic acid is a member. They have a fluorine atom at 
position 6 of the quinolone nucleus (Yao & Moellering, 1999). 
D N A gyrase, a type II D N A topoisomerase, is the target of fluoroquinolones. It is a 
tetrameric protein, comprising of two subunits A and two subunits B, being 
encoded by gyrA and gyrB genes, respectively and is essential in introducing 
negative supercoils to covalently closed D N A by breaking and then resealing DNA. 
Fluoroquinolones inhibit D N A supercoiling by interrupting D N A breakage and 
resealing. Type IV D N A topoisomerase is another target site of the 
fluoroquinolones. It consists of two parC subunits and two parE subunits, being 
encoded by parC and parE genes, respectively. They are responsible for relaxing 
the supercoiled D N A during replication (Yao & Moellering, 1999). 
Fluoroquinolones such as ciprofloxacin and ofloxacin are especially active against 
Gram-negative bacteria but less so against the Gram-positives. The more recently 
developed fluoroquinolones such as levofloxacin and sparfloxacin have increased 
activity against Gram-positive bacteria as well as anaerobes while maintaining 
their activity against Gram-negative bacteria (Yao & Moellering, 1999). 
Moxifloxacin and gemifloxacin are two new fluoroquinolones that are also more 
active against Gram-positive bacteria. Moxifloxacin is a methoxy-quinolone that 
acts on both D N A gyrase and topoisomerese IV, thereby making it more active 
and resistance to it less readily to develop (Schedletzky, Wiedmann & Heisig, 
1999). Gemifloxacin similarly targets both D N A gyrase and topoisomerase IV and 
is therefore more active than ciprofloxacin against Gram-positive bacteria but is 
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comparable to ciprofloxacin in activity against Gram-negative bacteria (Cormican 
& Jones, 1997; Hardy et a!., 2000; McCloskey etal” 2000; Heaton, Ambler & 
Fisher, 2000). 
Fluoroquinolones penetrate well into phagocytes, so that concentrations within 
neutrophils and macrophages are as high as 14 times the concentrations in 
serum. This feature accounts for their excellent in vivo activity against intracellular 
pathogens such as Salmonella (Yao & Moellering, 1999). 
Resistance to fluoroquinolones is due mainly to alteration of D N A gyrase and / or 
topoisomerase IV. Decrease in cell permeability and active efflux of drug can also 
lead to resistance (Yao & Moellering, 1999). 
Mutations in the genes coding for the subunits of gyrase and/or topoisomerase IV 
m a y confer resistance to quinolones. Mutations in gyrA gene have been detected 
in many fluoroquinolone-resistant bacteria. Most of the gyrA mutations have been 
located in a 130-bp sequence known as the quinolone resistance-determining 
region. Mutations in gyrA induce changes in the conformation of the binding site. 
Such changes may be important for quinolone-DNA gyrase interaction. Mutations 
in gryB only lead to low-level resistance (Quintiliani, S a h m & Courvalin, 1999). In 
Gram-negative bacteria, D N A gyrase is the primary target of fluoroquinolones 
while topoisomerase IV is the primary target of Gram-positive bacteria (Quintiliani, 
S a h m & Courvalin, 1999). Thus, gyrA mutations develop first followed by parC 
mutations in Gram-negative bacteria and the reverse is true for Gram-positive 
bacteria. 
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Decreased drug accumulation associated with changes in the outer membrane 
confers low-level resistance to quinolones as well as other structurally unrelated 
drugs. An intrinsic efflux system, which pumps the drug out of the cell leading to 
quinolone-resistance, has been found in some bacterial species (Quintiliani, 
S a h m & Courvalin, 1999). 
D. p-Lactams 
P-Lactams are a large group of antimicrobial agents that have a broad spectrum 
of activity (Dax, 1997). The classic penicillins such as penicillin and ampicillin 
have limited activity against Gram-positive and Gram-negative bacteria, 
respectively. The cephalosporins, especially the more recently developed ones 
such as ceftriaxone and ceftazidime, are especially active against the Gram-
negatives. The carbapenems that include imipenem and meropenem have both 
Gram-positive and Gram-negative activity and are very active against 
Pseudomonas aeruginosa. 
p-Lactams act by binding to penicillin binding proteins (PBPs) thereby inhibiting 
transpeptidase enzymes necessary for peptidoglycan synthesis in the bacterial 
cell wall. Cell wall synthesis is thus inhibited, resulting in death of the bacterial cell. 
As PBPs are absent in human cell, p-lactams are not toxic to man (Yao & 
Moellering, 1999). 
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The most common mechanism of resistance to these (3-lactam drugs is due to the 
production of p-lactamase enzymes that cleave the p-lactam ring. p-Lactamase 
genes are usually present on transferable plasmids, however, they can also be 
borne on the chromosome. Other mechanisms of resistance include development 
of altered PBPs, acquisition of a novel PBP with reduced affinity to p-lactams, 
change in the outer membrane proteins of Gram-negative organisms and active 
efflux (Quintiliani, Sahm & Courvalin’ 1999). 
E. Aminoglycosides 
Aminoglycosides are a group of antibacterial agents that are active primarily 
against aerobic Gram-negative bacilli (Dax, 1997). Amikacin, netiIimidn and 
gentamicin are the most common aminoglycosides used clinically. They act by 
binding irreversibly to the bacterial 30S ribosomal subunit so that protein 
synthesis is inhibited. They also cause misreading of genetic code leading to 
production of nonsense proteins. Aminoglycoside resistance is also mainly due to 
production of enzymes 
(aminoglycoside-modifying enzymes) that inactivate the aminoglycosides by 
phosphorylation, acetylation or adenylylation. Other mechanisms of resistance 
include ribosomal modification or decreased uptake of aminoglycoside into the 
bacterial cell (Quintiliani et a/. 1999；.. 
F. Salmonella sp 
a. Microbiology and clinical significance 
Salmonellae are Gram-negative bacilli belonging to the family Enterobacteriaceae. 
Their classification is complicated and their nomenclature confusing. However, 
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there is now a consensus that Salmonella consists of only one species S. enterica 
(Le Minor, 1984) with seven subspecies (Le Minor, 1988). Within the subspecies, 
they are classified into serotypes according to lipopolysaccharide (O), flagella (H) 
and virulence (Vi) antigens. Salmonella serotypes that causes human infections 
are often given names for easy reference. For example, Salmonella typhimurium 
is now referred to as Salmonella enterica subspecies enterica serotype 
Typhimurium or in brief, Salmonella Typhimurium. 
Salmonellae are divided into enteric fevers group and gastroenteric group 
according to their pathogenicity. The enteric fevers group comprises of S. Typhi 
and S. Paratyphi A, B and C that are mainly human pathogens. They cause a 
severe generalized illness which is predominantly septicaemic. In contrast, the 
gastroenteric group comprises of animal pathogens that cause gastroenteritis or 
food poisoning which is usually self-limiting although they can become invasive 
occasionally causing serious illnesses such as septicaemia and meningitis 
(Thomas, 2002). 
b. Antimicrobial susceptibilities 
The level of resistance among salmonellae varies in different countries and when 
isolated from different sites or patients. It also varies among different serotypes 
(Table 1-1). The previous studies during 1973-1982 and 1985-1988 show 
that there was an increase in the rates of resistance to ampicillin (12% vs 16%), 
tetracycline (15% vs 36%) and chloramphenicol (6% vs 19%) (Ling et al., 1987, 
1991). As for specific serotypes, S. Typhi and S. Enteritidis remained fairly 
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susceptible (Ling et a/., 1996; 1998). Except for tetracycline and sulfonamides 
where resistance is up to 4 9 % in S. Derby, other antibiotics are quite active 
against this serotype (Ling et al., 2001b). In contrast, S. Typhimurium is resistant 
to most antibiotics. What is more worrying is the appearance of strains of S. 
Typhimurium and S. Derby that have reduced susceptibility to ofloxacin and/or 
ciprofloxacin (Ling et al., 2001a; 2001b). 
In constrast, of the 62 strains of S. Typhi isolated during 1997-1999 in Japan, 
19% were resistant to ampicillin, chloramphenicol or cotrimoxazole (Kenji et al., 
2001). There were less strains of S. Paratyphi A (n=37) isolated and of these, only 
3 % were resistant to any of these three antibiotics (Kenji et al., 2001). 
Of the 119 non-typhoidal salmonellae isolated from blood cultures of children in 
two hospitals in Malaysia during 1991-2001, 4 3 % were S. Enteritidis (Lee et al., 
2003). It is therefore not surprising to find a low level of resistance among these 
isolates. Only 1 % was resistant to ampicillin and 5 % to cotrimoxazole, although 
more were resistant to chloramphenicol (7%) or tetracycline (11%). 
Chiu and colleagues (2002) specifically looked at S. Choleraesuis, a serotype that 
is known to be more invasive and thus frequently causes blood stream infection. 
They noted a substantial increase in the rates of resistance as from 1991, where 
resistance to ampicillin, chloramphenicol or cotrimoxazole varies from 3 0 % to 
>80%. There is a huge increase in the prevalence of ciprofloxacin resistance to 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































There was an increase in the proportion of strains having reduced susceptibility to 
ciprofloxacin (MIC > 0.125 pg/ml) from Finnish travelers returning from southeast 
Asia from 4 % in 1995 to 2 4 % in 1999 (Hakanen etal.,2001). The increase in the 
proportion of such strains from those who returned from Thailand was alarming, 
being 6 % in 1995 and 5 0 % in 1999 (Hakanen et al., 2001). 
Although only 29 strains of Salmonella sp isolated from stools of diarrhoeal 
patients in 1997-1998 in West Kenya were tested in the report by Shapiro and 
colleagues (2001) 21-60% were resistant to ampicillin, chloramphenicol, 
tetracycline, gentamicin or cotrimoxazole, indicating a problem of antibiotic 
resistance among salmonellae in this region. 
Cormican and colleagues (2002) noted that S. Bredeney, a rare human pathogen 
became the third most common Salmonella serotype in 1998 in Ireland. Only 1-
2 % were resistant to ampicillin or tetracycline although resistance to 
cotrimoxazole was much higher at 21%. 
Cruchaga et al. (2001) noted that the incidence of isolates from animals being 
antibiotic resistant is higher than that from humans or food (Table 1-1). S. 
Enteritidis remains quite susceptible to antimicrobial agents except nalidixic acid 
(23% resistant), ampicillin (26% resistant) and sulfonamides (33% resistant). The 
authors noted that antibiotic resistance among S. Typhimurium and S. Hadar 
isolates is high, being 8 1 % and 65%, respectively to ampicillin, and 8 9 % and 90%, 
respectively to tetracycline. It is interesting to note that more S. Hadar isolates are 
resistant to nalidixic acid than S. Typhimurium (81% vs 28%). 
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The study by Threlfall and colleagues (2003) shows the percent of different 
Salmonella serotypes that are resistant to 11 antimicrobial agents. These strains 
were collected over 10 European countries in 2000. Although it is well established 
that S. Typhimurium is the serotype that has the highest antibiotic resistance rates 
(ranging from 8 % resistant to nalidixic acid to 6 4 % to tetracycline as observed by 
Threlfall et al. (2003))，it is interesting to note that of the 622 S. Hadar isolates 
tested, a considerable proportion is resistant to tetracycline (73%), nalidixic acid 
(57%) or ampicillin (35%). The corresponding figures for S. Typhimurium (total 
number tested = 6777) are 64%, 8 % and 59%, respectively. The proportion of 
nalidixic acid-resistant S. Virchow is comparable to that of nalidixic acid-resistant 
S. Hadar, being 53%, while that of S. Blockley is lower, being 17%. 
Resistance to nalidixic acid in salmonellae ranges from a low of 0.7% in S. 
Enteritidis during 1986-1996 in Hong Kong to a high of 34% in 1998 in Spain (Ling 
et al., 1998; Cruchaga et al., 2001). Resistance to 0.12 |jg/ml of ciprofloxacin was 
generally low (0-2%) although an alarming rate of 6-11% was reported from Hong 
Kong and in travelers returning to Finland from southeast Asia (Hakanen et a I., 
2001). 
G. Escherichia coli 
a. Microbiology and clinical significance 
Escherichia coli is also a Gram-negative bacteria within the family 
Enterobacteriaceae. It is the most common facultative bowel commensal of man 
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and animals. It causes infection when present in other parts of the body. The most 
c o m m o n infections caused are urinary tract infection and septicaemia. It is also a 
c o m m o n cause of neonatal meningitis. Similar to salmonellae, E. coli strains can 
also be differentiated into serotypes according to their 〇 and H antigens. Certain 
serotypes of E. coli can cause diarrhoea. These include Shiga toxin-producing E. 
coli (STEC) 0157 H7, the enterohemorrhagic E. coli (EHEC), enteroinvasive E. 
coli (EIEC), enteropathogenic E. coli (EPEC) such as 0158 H23 and 
enterotoxigenic E. coli (ETEC) (Bopp et a I., 1999). 
b. Antimicrobial susceptibilities 
E coli is naturally sensitive to almost all antimicrobial agents that are active 
against Gram-negative bacteria. However, with the increased use of these drugs, 
it has developed resistance to most of them. Strains that are isolated in the 
hospital are also resistant to more antibiotics than those that are isolated in the 
community. 
Ampicillin, the first-line antibiotic that has been used successfully in treating E. coli 
infections, is now no longer reliable since more than 3 0 % of strains are resistant 
to this drug, although only 18% were resistant more than 30 years ago (Table 1-2). 
Resistance to other older drugs such as tetracycline or chloramphenicol is also 
generally high (up to 60%) aKhough resistance rates as low as 4 % have been 
detected in some countries (Table 1-2). 
Resistance to the second and even third generation cephalosporins in E. coli has 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































isolated from blood during 1984-1997 were resistant to cephamandole and 
cefuroxime respectively while 2 % were resistant to ceftriaxone, cefotaxime or 
ceftazidime (Ling et ai, 2001). Similar figures were obtained in the U S albeit in 
strains from patients staying in intensive care units (ICU) while those from patients 
in non-ICU wards were lower (Karlowsky et a!., 2003a). 
Resistance to gentamicin varied widely from 0 % in isolates from children in 
Oklahoma in U S in the 1970s to 2 6 % from blood cultures in Hong Kong during 
1984-1997 (Table 1-2). Resistance to amikacin is generally low, ranging from less 
than 1 % in the U S or Europe to 18% in Poland. Resistance to cotrimoxazole is in 
general between 8 % in Veneto, Italy to 3 1 % in Poland but is alarming at 80-91% 
in Tanzania (Table 1-2). Ciprofloxacin-resistance is maintained at below 10% 
although it is 11% in strains causing hospital-acquired urinary tract infection in 
Poland (Table 1-2). Similarly, resistance to the third generation cephalosporins 
ceftriaxone, cefotaxime or ceftazidime is low, being 6 % or less, but again with the 
exception of strains causing complicated community-acquired urinary tract 
infection in Poland (Table 卜2). 
It is interesting to note that resistance among E. coli strains causing hospital-
acquired urinary tract infection is less than that among strains causing 
complicated community-acquired urinary tract infection (Hryniewicz et a!., 2001). 
This probably shows that antibiotic usage in complicated infections may often be 
more than in hospital-acquired infections, leading to higher selective pressure. 
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H. Pseudomonas aeruginosa 
a. Microbiology and clinical significance 
Pseudomonas aeruginosa is a Gram-negative non-fermentative rod that is 
naturelly resistant to many antibiotics. It is a normal flora of the skin and 
gastrointestinal tract. However, under certain compromising situations such as 
trauma, burns or immune deficiency, it can cause wound or systemic infections. 
Because of its innate antibiotic-resistance, it has remained as a major cause of 
nosocomial infections and treatment of infections caused has been difficult due to 
limited choice of chemotherapy. 
b. Antimicrobial susceptibilities 
P aeruginosa is intrinsically resistant to many antimicrobial agents. Treatment of 
Pseudomonas infections is often by a combination of antipseudomonal p-lactams, 
aminoglycosides or fluoroquinolones, although monotherapy with broad-spectrum 
P-lactams such as ceftazidime and imipenem has been used. 
In contrast to Salmonella sp and E coli, P aeruginosa is naturally resistant to 
many commonly used antibiotics. In the 13-year study (1984-1997) of blood 
culture isolates in Hong Kong, 516 isolates of P aeruginosa were available for 
susceptibility testing (Ling, Liu & Cheng, 2001). Resistance rates were in general 
low (<5%) expcet for cephalosporins that are not anti-pseudomonal (cefotaxime 
and ceftriaxone). Of the two anti-pseudomonal cephalosporins，ceftazidime is 
more active (4% resistant) than cefoperzone (10% resistant). All were susceptible 
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to amikacin, 5 % were resistant to gentamicin and 1 % was resistant to 
ciprofloxacin (Table 1-3). 
Much higher resistance rates are noticed in Taiwan even 18 years ago (Peng & 
Lin,1987). More than 10% of the 412 P aeruginosa isolates were resistant to the 
antibiotics tested except ceftazidime where 7 % were resistant. However, the 
authors did not state the breakpoints used in defining the percentage resistance 
nor the sites where the isolates were isolated from. 
Three large surveys of P aeruginosa were carried out from 1986 to 1999 in the 
United Kingdom (Chen et al., 1995; Spencer, 1996; Henwood et al., 2001). 
These studies show that the average resistance rates differ, varying from 1 % 
resistance to amikacin in ICU and 1 % resistance to ceftazidime in out-patients in 
1999 to 20-22% resistance to carbenicillin or ceftazidime in ICU in 1993. In 
general, resistance rates are lower in isolates from out-patients than those from 
in-patients (non-ICU) especially for the penicillins and ceftazidime (Chen ef al., 
1995) (Table 1-3). Spencer (1996) noted that the antimicrobial susceptibilities 
varied according to the infections caused. P aeruginosa isolates from cystic 
fibrosis patients are usually more resistant (Spencer et al., 1996), followed by 
strains from patients in renal units. However, no significant change in 
susceptibility of P aeruginosa is noted over the 8-year study period of 1986-1993. 
The study by Henwood and colleagues (2001) shows that resistance is rare in the 
United Kingdom during 1999 (<12% to most antibiotics tested) although there are 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Although resistance rates are higher from strains isolated from in-patients than 
those from outpatients, the difference is only significant for p-lactams. 
Reports from the United States show that resistance rates are quite high even for 
isolates from non-ICU specialties (Table 1-3). Such rates range from 6 % to 
imipenem to 5 8 % to gentamicin. Resistance to ciprofloxacin has alarmingly 
increased, from 7 % in 1995 to 4 1 % in 1999. (Gentry, Flournoy & Reinert, 2002). 
Rapp and colleagues (2001) noticed only small increases in resistance to 
piperacillin and imipenem although resistance rates varied throughout 1991-2000 
for different antimicrobial agents. One of the factors that led to an increase in 
resistance to fluoroquinolones (almost 3 0 % resistance to ciprofloxacin) in the 
United States is the increasing fluoroquinolone use in recent years (Karlowsky et 
al., 2003a). As noted in other studies, resistance is lower in non-ICU than ICU 
isolates: 13% and 17% to ceftazidime; 13% and 2 0 % to imipenem; and 14% and 
2 1 % to meropenem, respectively. However, resistance rates to amikacin are 
similar, being 7-8%. 
P aeruginosa isolates from N e w Zealand were quite susceptible to antimicrobial 
agents although the number tested is small (42) (Morris et al., 1997) (Table 1-3). 
Rodriquez et al. (2002) found that much more isolates were resistant in 
Venezuela than in Paraguay and they attributed this to inappropriate use of 
antimicrobial agents in Venezuela. 
The large global S E N T R Y surveillance programme during 1997-1999 involves 
antimicrobial susceptibility testing in five regions/countries (Gales et al., 2001). 
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Resistance is overall high especially in Latin America except for resistance to 
amikacin in the Asia Pacific region, Canada and United States (4-5%). 
Resistance to ciprofloxacin varies from 16% in the Asia Pacific region to 3 7 % in 
Latin America, resistance to ceftazidime form 2 8 % in Canada to 3 4 % in Latin 
America and resistance to imipenem from 12% in the Asia Pacific region to 2 4 % 
in Latin America. The authors noted that no single agent is effective against 
> 9 0 % of strains except amikacin in some regions. 
J. Objectives 
In this study, w e aimed: 
a) to investigate the ability of fluoroquinolones, (3-lactams and aminoglycosides to 
select for resistant strains of salmonellae, E coli and P aeruginosa; 
b) to determine the extent of cross-resistance to drugs of the same family; and 
c) to compare the ease with which each of the three microorganisms tested 
developed resistance. 
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Chapter 2 MATERIALS AND METHODS 
A. BACTERIAL STRAINS 
Forty isolates each of Salmonella sp, Escherichia coli and 30 strains of 
Pseudomonas aeruginosa were studied. These were all single patient isolates. 
Salmonella strains were isolated from patients at the Prince of Wales Hospital 
(PWH) during 1997-2000. P. aeruginosa and E. coli were isolated from patients 
visiting general practitioners throughout Hong Kong during 2000-2001. These 
isolates were isolated from various specimens and identified according to 
standard procedures and then stored on nutrient agar slants at room temperature 




Salmonella isolates were identified by the API 20E system (bioMerieux, Marcy-
1'Etoile, France) according to the manufacturer's instructions. A single overnight 
colony on MacConkey agar (Oxoid, Basingstoke, UK) was emulsified in 1 ml 
distilled water to give a homogeneous bacterial suspension and inoculated into an 
API 20E strip. 
After incubation at 37°C for 18 - 24 hours, results were read and scored to 
give a numerical profile. Identification was made by matching the numerical 
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profile of the isolate with that in the Analytical Profile Index (API 20E 2.0，2001) 
supplied by the manufacturer. 
The identification of Salmonella isolates was confirmed by the slide agglutination 
test using specific Salmonella O and H antisera (Murex Biotech Limited). An 
overnight colony was emulsified in a loopful of saline on a glass slide and was 
then mixed with a loopful of antiserum. A positive reaction was indicated by the 
appearance of whitish clumps of agglutination. 
ii) Escherichia coli 
E coli isolates were identified by the API 20E system as described above. 
iii) Pseudomonas aeruginosa 
P aeruginosa isolates were identified by the oxidase test and API 20 NE 
system (bioMerieux). 
All oxidase-positive strains were identified by API 20NE. An overnight colony on 
MacConkey agar was emulsified in 2 ml 0.85% NaCI solution to give turbidity 0.5 
McFarland standard and inoculated into an API 20 N E strips. After incubation at 
3 / C for 24 hours, results were read and scored to give a numerical profile. 
Identification was made by matching the numerical profile of the isolate with that 
in the Analytical Profile Index I (API 20 NE 2001) supplied by the manufacturer. 
b. Antimicrobial susceptibility testing 
i) Determination of minimal inhibitory concentrations (MICs) of antibiotics 
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1) Preparation of antibiotic plates 
Antibiotics were dissolved by using different solvents as shown in Table 11-1, 
diluted with distilled water to give a stock concentration of 40,000 mg/l. Mueller-
Hinton agar (MHA) (Oxoid) powder was added to an appropriate volume of 
distilled water according to the manufacturer's instruction and then autoclaved 
and allowed to cool to 45°C to 50°C. An appropriate volume of antibiotic stock 
solution was added to give molten M H A to the desired final concentration as 
shown in Table 11-2. 
2) Preparation of inoculum 
A few overnight colonies on MacConkey agar were emulsified in 1 ml saline to 
turbidity similar to that of a MacFarland 0.5 standard. This was then diluted ten-
fold using sterile saline and used as the inoculum. 
3) Inoculation of plates 
Antibiotic plates were inoculated with the inoculum prepared as described above 
using a multipoint inoculator (MIC 2000 Dynatech) that delivered 1x 10'^ cfu per 
spot onto the agar. The plates were incubated at 37°C for 18-24 hours before 
results were read. The standard strains used included Salmonella Typhimuhum 
ATCC13311, E C O / / A T C C 25922, A T C C 35218 and N C T C 10418 and P 
aeruginosa A T C C 27853. 
4) Reading of results 
25 


















* distilled water 
Solvent 
0.1 N NaOH 
0.1 N NaOH 
0.1 N NaOH 
0.1 N NaOH 
0.1 N NaOH 









Table 丨丨-2 Antibiotics and their concentrations to be tested 
Antibiotic Concentration mg/l  
From To  
Fluoroquinolones 
Ciprofloxacin 0.0075 4 
Gemifloxacin 0.03 4 
Levofloxacin 0.015 4 
Moxifloxacin 0.03 64 
Norfloxacin 0.03 64 
Ofloxacin 0.015 4 
B-Lactams 
Cefotaxime 0.015 8 
Ceftazidime 0.03 8 
Ceftriaxone 0.015 8 
Meropenem 0.03 8 
Aminoglycosides 
Amikacin 0.12 16 
Gentamicin 0.06 4 
Netilmicin 0.06 4 
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MIC (minimal inhibitory concentration) is the lowest concentration of antibiotic 
inhibiting visible growth on the inoculation spot. 
ii) Determination of the antimicrobial susceptibility of Salmonella sp, 
Escherichia coli and Pseudomonas aeruginosa by the breakpoint method 
The susceptibility of S Typhimurium, E coli and P aeruginosa to different 
antibiotics was determined by the breakpoint method according to the 
recommendations of the National Committee on Clinical Laboratory Standards 
(NCCLS, 2000). This was performed as for determination of the MICs except that 
breakpoint concentrations of antibiotics were used. Complete inhibition of growth 
at the inoculation spot indicated that the strain was sensitive to the concentration 
of antibiotic in the agar. 
c. Effects of antimicrobial agents on the development of resistant mutants 
In order to study the effects of different antimicrobial agents on the development 
of resistant mutants, all isolates of Salmonella, E coli and P aeruginosa as 
described in section A above were subjected to daily passage in broth containing 
increasing serial two-fold dilutions of an antibiotic starting at a concentration of 
0.75X10—2 mg/l to 128 mg/l. The overnight broth culture was then inoculated onto 
agar plate containing antibiotics at breakpoint concentrations as listed in Table II-
3. An overnight colony of each strain was inoculated into 3 ml saline to a turbidity 
that matched that of a 0.5 McFarland standard and then diluted to a concentration 
of approximately 10®cfu/ml. Two hundred micro-liter of this bacterial suspension 
was inoculated into 1 ml of M H B (Mueller Hinton Broth) containing the antibiotic 
and incubated overnight at 37°C with shaking. This passage was continued until 
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Table 1丨-3 Antibiotics and their breakpoint concentrations tested 





Moxifloxacin 1, 4 












the overnight broth became clear and on subculture onto M H A , no growth was 
obtained. The concentration of antibiotic in the broth was noted. Susceptibility of 
daily broth culture to the antibiotic was assessed by the breakpoint method as 
described above. 
W h e n the culture showed resistance to the breakpoint concentrations of any of 
the antibiotics tested ie, when resistant mutants started to appear, the 
concentration of the antibiotic in which the culture was grown was noted. This 
concentration was compared with the MIC of the antibiotic to the strain and 
expressed as the number of times the MIC (Xs MIC). The concentration range at 
which strains started to develop resistance, the concentration at which 5 0 % of 
strains developed resistance and that at which 9 0 % of strains developed 
resistance, all expressed as Xs MIC, were determined. The total number of strains 
that developed resistance to any of the antibiotics at a particular concentration 
and the number of strains that survived when the concentrations reached 128 
mg/l were also noted. The former was used to calculate the percentage of strains 
that developed resistance in the presence of an antibiotic and the latter to give the 
percentage of strains that were killed. The concentration, which was bactericidal 
for each strain, was noted. This concentration was also compared with the MIC 
and expressed as Xs MIC. The range of concentration at which strains started to 
be killed, the concentrations at which 5 0 % and 9 0 % of strains were killed, all 
expressed as Xs MIC, were calculated. 
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The same strains were also subcultured in broth containing no antibiotic for the 
same period to serve as control. 
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Chapter 3 Results 
A. Antimicrobial susceptibilities 
Table IH-1 shows the susceptibility of 12 antimicrobial agents to 40 isolates of 
Salmonella sp isolated from patients in the Prince of Wales Hospital during 1997-
2000. All isolates could only be inhibited by 0.24 mg/l or less of norfloxacin or the 
newer fluoroquinolones gemifloxacin and moxifloxacin. The M I C 5 0 of ciprofloxacin 
was lowest (0.015 mg/l) while those of levofloxacin, moxifloxacin, norfloxacin and 
ofloxacin was 0 . 0 6 mg/l. The M I C 9 0 of ciprofloxacin was also the lowest 0.015 
mg/l,while that of moxifloxacin was 0.12 mg/l. 
These isolates could be inhibited by 0.25 mg/l or less of cefotaxime or ceftriaxone 
and 0.5 mg/l or less of ceftazidime. Both the M I C 5 0 and M I C 9 0 of ceftriaxone were 
lowest (0.06 mg/l and 0.12 mg/l, respectively) while those of ceftazidime were 
highest (0.5 mg/l). They were also quite susceptible to gentamicin or netilmicin 
(MIC range = 0.5-2 mg/l) or amikacin (MIC range = 0.5-8 mg/l). The M I C 5 0 and 
M I C 9 0 of netilmicin were 0.5 mg/l and 1 mg/l, respectively, while those of 
gentamicin were 2-fold higher, being 1 mg/l and 2 mg/l, respectively. The M I C 5 0 
and M I C 9 0 of amikacin 4-fold higher than those of gentamicin (4 mg/l and 8 mg/l, 
respectively). 
The susceptibilities of 40 E coli strains isolated from patients of general 
practitioners throughout Hong Kong during 2000-2001 to 12 different antimicrobial 
agents are shown in Table 111-2. 
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Table 111-1 Susceptibilities of 40 isolates of Salmonella sp to 12 antimicrobial 
agents 
Antimicrobial agent Mg/I MICso MICgo MIC range 
Fluoroquinolones 
Ciprofloxacin 0.015 0.015 0.0075-0.12 
Gemifloxacin 0.03 0.06 0.015-0.12 
Levofloxacin 0.06 0.06 0.03-0.06 
Moxifloxacin 0.06 0.12 0.03-0.12 
Norfloxacin 0.06 0.06 0.03-0.25 
Ofloxacin 0.06 0.06 0.03-0.06 
I3-Lactams 
Cefotaxime 0.12 0.25 0.015-0.25 
Ceftazidime 0.5 0.5 0.06-0.5 
Ceftriaxone 0.06 0.12 0.015-0.12 
Aminoglycosides 
Amikacin 4 8 0.5-8 
Gentamicin 1 2 0.5-2 
Netilimicin 0.5 1 0.5-2 
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Table 111-2 Susceptibilities of 40 isolates of Escherichia coli to 12 antimicrobial 
agents 
Antimicrobial Mg/l  
agent M I C 5 0 M I C 9 0 MIC range 
Fluoroquinolones 
Ciprofloxacin 0.03 0.03 0.0075-0.03 
Gemifloxacin 0.015 0.03 0.015-0.03 
Levofloxacin 0.03 0.03 0.03-0.25 
Moxifloxacin 0.06 0.06 0.03-1 
Norfloxacin 0.06 0.12 0.06-0.5 
Ofloxacin 0.06 0.12 0.03-0.12 
B-Lactams 
Cefotaxime 0.06 0.06 0.015-0.12 
Ceftazidime 0.12 0.12 0.015-0.25 
Ceftriaxone 0.06 0.06 0.015-0.25 
Aminoglycosides 
Amikacin 1 2 1-4 
Gentamicin 1 2 0.25-2 
Netilimicin 0.25-1 
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Ciprofloxacin started to inhibit these strains at the lowest concentration (0.0075 
mg/l) followed by gemifloxacin (0.015 mg/l). Gemifloxacin, moxifloxacin and 
ofloxacin started to inhibit these strains at 0.03 mg/l while norfloxacin started to 
inhibit strains at 0.06 mg/l. All strains could be inhibited by 0.03 mg/l of 
ciprofloxacin and gemifloxacin but only at 0.5 mg/l of norfloxacin and 1 mg/ of 
moxifloxacin. The M I C 5 0 of the six fluoroquinolones tested ranged from a low of 
0.015 mg/l of gemifloxacin to a high of 0.06 mg/l of moxifloxacin, norfloxacin and 
ofloxacin. The MIC 90 of these drugs ranged from 0.03 mg/l of ciprofloxacin, 
gemifloxacin and levofloxacin to 0.12 mg/l of norfloxacin and ofloxacin. 
All three cephalosporins started to inhibit the growth of all E coli strains at 0.015 
mg/l and could inhibit all strains at < 0.25 mg/l. The M I C 5 0 and M I C 9 0 of 
cefotaxime and ceftriaxone were 0.06 mg/l while those of ceftazidime were 2-fold 
higher, being 0.12 mg/l. 
Both gentamicin and netilmicin started to inhibit the growth of E coli strains at 0.25 
mg/l but amikacin started to inhibit strains at 1 mg/l. All strains could be inhibited 
by 1 mg/l of netilmicin but 2 mg/l of gentamicin or 4 mg/l of amikacin. The M I C 5 0 
and M I C 9 0 of netilmicin were 0.25 mg/l while those of both amikacin and gentacin 
were 1 mg/l and 2 mg/l, respectively. 
Table 111-3 shows the MIC range of 30 P aeruginosa strains isolated from patients 
of general practitioners throughout Hong Kong during 2000-2001 to 11 different 
antimicrobial agents. 
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All strains could be inhibited by 0.12 mg/l of moxifloxacin or norfloxacin but only 
by 2 mg/l of ciprofloxacin. Fifty percent of strains could be inhibited by 0.06 mg/l of 
ciprofloxacin, moxifloxacin or norfloxacin while 9 0 % could only be inhibited by 1 
mg/l of ciprofloxacin or ofloxacin. All could be inhibited by 2 mg/l of ceftazidime or 
1 mg/l of meropenem. Meropenem could inhibit 5 0 % of strains at 0.25 mg/l while 
ceftazidime could inhibit 5 0 % at 2 mg/l. All strains were inhibited by 2-8 mg/l of 
the aminoglycosides. Fifty percent of strains were inhibited by 1 mg/l of amikacin 
and 2 mg/l of netilmicin. The MICgo value for these three aminoglycosides was 2-
fold higher than the corresponding MICso-
B. Effects of fluoroquinolones on the development of resistance 
Forty stains each of Salmonella sp, and E coli and 30 strains of P aeruginosa 
were grown in the presence of fluoroquinolones, (3-lactams and aminoglycosides 
to test for the ability of these drugs to select for resistance. The concentration of 
the selecting drug at which a strain started to develop resistance was compared 
to the MIC of this drug to the strain and expressed as the number of times that of 
the MIC (Xs MIC). The range of Xs MIC at which all the tested strains developed 
resistance, the Xs MIC at which 5 0 % and 9 0 % of strains developed resistance 
and the percentage of strains that developed resistance per passage (calculated 
by dividing the percentage of resistant strains by the total number of passages 
taken for the strains to become resistant) are shown in Tables III- 4 -111-18. They 
were also grown in broth containing no antibiotic to serve as control. No strain 
developed resistance to any of the antibiotics when subcultured in broth 
containing no antibiotic. 
36 
Table 111-3 Susceptibilities of 30 isolates of Pseudomonas aeruginosa to 11 
antimicrobial agents 
Antimicrobial Mg/I 
agent MICso MICgo MIC range 
Fluoroquinolones 
Ciprofloxacin 0.06 1 0.06-2 
Gemifloxacin 0.25 0.25 0.03-0.5 
Levofloxacin 0.25 0.25 0.06-0.5 
Moxifloxacin 0.06 0.12 0.03-0.12 
Norfloxacin 0.06 0.12 0.03-0.12 
Ofloxacin 0.5 1 0.12-1 
{3-Lactams 
Ceftazidime 2 2 0.25-2 
Meropenem 0.25 0.5 0.25-1 
Aminoglycosides 
Amikacin 1 2 0.5-4 
Gentamicin 1 2 0.12-2 
Netilimicin 2 4 0.25-8 
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a. Salmonella sp 
Strains resistant to all the six fluoroquinolones tested developed when the parent 
strain was passaged in broth containing each of the fluoroquinolones indicating 
that there was cross-resistance to all the fluoroquinolones. 
W h e n strains were grown in the presence of gemifloxacin, moxifloxacin or 
norfloxacin, most strains developed resistance to the sensitive breakpoint 
concentration of these fluoroquinolones. Resistance developed to gemifloxacin 
per passage in gemifloxacin was 1.6% which was the highest while resistance 
developed to the other five fluoroquinolones per passage ranged from 0.8% to 
1.2% (Table lll-4a). Similarly, resistance developed to moxifloxacin or norfloxacin 
per passage in moxifloxacin or norfloxacin was highest, being 6.5% and 6.7%, 
respectively while resistance developed to the other fluoroquinolones were 2.3%-
4.8% and 3.2% and 6.4%, respectively. In contrast, resistance to levofloxacin 
developed per passage in levofloxacin was lowest, being 1.8% as compared to 
resistance to other fluoroquinolones developed when passaged in levofloxacin 
(2.0%-3.9%). 
Gemifloxacin-resistant strains started to appear at a low of 2Xs MIC of all of the 
fluoroquinolones tested except moxifloxacin while resistance to moxifloxacin 
started to appear at the MIC of ofloxacin. Resistance to ciprofloxacin or 
levofloxacin developed at a high of 128Xs MIC of gemifloxacin. 
Resistance developed to gemifloxacin per passage in any of the six 
fluoroquinolones was highest among resistance developed to other 
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Table IH-4a. Ability of fluoroquinolones to select strains of Salmonella sp resistant to sensitive breakpoint concentration of 
fluoroquinolones. 
Became resistant Xs M IC at which resistance , 
, � . � ％ that , , % Resistance 
„ , , to sensitive developed No. of 
Selected by . , became developed per 
breakpoint In 5 0 % In 9 0 % passages 
. ^ Range resistant passage  
concentration of “ of strains of strains  
Ciprofloxacin Ciprofloxacin 8 -256 64 128 38 11 3.4 
Gemifloxacin 2 -64 8 32 68 9 7.5 
Levofloxacin 8 -256 64 256 35 11 3.1 
Moxifloxacin 4 -32 16 32 65 8 8.1 
Norfloxacin 4 -64 64 64 52 9 5.8 
Ofloxacin 8 -256 ^ 64 ^ 1J ^  
Gemifloxacin Ciprofloxacin 128-
1024 1024 10 13 0.8 
Gemifloxacin 2-64 8 32 15 9 1.6 
Levofloxacin 128-
1024 256 1024 10 13 0.8 
Moxifloxacin 4 - 1 0 2 4 16 512 15 13 1.2 
Norfloxacin 32 -512 32 512 13 12 1.0 
Ofloxacin 4 - 1 0 2 4 256 1024 13 ^  
Levofloxacin Ciprofloxacin 16-64 32 64 23 11 2.0 
Gemifloxacin 2 -16 8 16 35 9 3.9 
Levofloxacin 32 -128 64 64 20 11 1.8 
Moxifloxacin 4 -16 16 16 50 9 5.6 
Norfloxacin 16-128 32 64 30 11 2.7 
Ofloxacin 32 32 30 r \ ^  
Moxifloxacin Ciprofloxacin 32 -128 32 128 4 0 12 3.3 
Gemifloxacin 2 -64 8 16 48 10 4.8 
Levofloxacin 32-256 64 128 30 13 2.3 
Moxifloxacin 4 -64 16 32 65 10 6.5 
Norfloxacin 16-128 32 64 48 13 3.7 
Ofloxacin 8 -128 32 64 48 11 « 
Norfloxacin Ciprofloxacin 16-256 64 256 50 13 3.8 
Gemifloxacin 4 -64 16 64 70 11 6.4 
Levofloxacin 64 -512 128 256 45 14 3.2 
Moxifloxacin 1 -128 16 64 70 11 6.4 
Norfloxacin 8 -128 64 64 80 12 6.7 
Ofloxacin 4 - 2 5 6 64 ^ ^ 12 4.8 
Ofloxacin Ciprofloxacin 16-64 32 64 28 11 2.5 
Gemifloxacin 2 -32 8 16 58 9 6.4 
Levofloxacin 32-64 64 64 25 11 2.3 
Moxifloxacin 4 -32 8 16 53 10 5.3 
Norfloxacin 8 -64 32 64 43 11 3.9 
Ofloxacin ^ M 40 V\ 3.6 
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fluoroquinolones, ranging from 1.6% in the presence of gemifloxacin to 7.5% in 
the presence of ciprofloxacin. In contrast, resistance developed to levofloxacin per 
passage in any of the six fluoroquinolones was lowest, ranging from 0.8% in the 
presence of gemifloxacin to 3.2% in the presence of norfloxacin. 
Similar results were obtained for strains that became resistant to resistant 
breakpoints of the fluoroquinolones tested (Table lll-4b). However, the percentage 
of resistance that developed per passage was lower, being usually <1%. No 
resistance to levofloxacin developed in the presence of gemifloxacin. 
Resistance started to develop to gemifloxacin at a low of 4Xs MIC of gemifloxacin, 
ciprofloxacin, norfloxacin or ofloxacin while resistance to levofloxacin started to 
develop at 512Xs MIC of ciprofloxacin, norfloxacin or ofloxacin. 
All strains could be killed by 128 mg/l of gemifloxacin only while 2%-17% of 
strains still survived at 128 mg/l of the other five fluoroquinolones (Table III-5). 
However, strains started to be killed at a low of 1Xs MIC of ofloxacin to a high of 
8Xs MIC of moxifloxacin or norfloxacin. 
b. Escherichia coli 
Resistance to all the six fluoroquinolones developed in all the E coli strains tested 
when they were passaged in each of the fluoroquinolones indicating cross-
resistance among these drugs in the organism. 
> 
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Table ll l-4b. Ability of fluoroquinolones to select strains of Salmonella sp resistant to resistant breakpoint concentration of 
fluoroquinolones. 
Became resistant Xs MIC at which resistance 
, . 1 1 • � ％ that % Resistance 
… �L to resistant developed No. of 
Selected by , , . , ： became developed per breakpoint ^ In 5 0 % In 9 0 % passages 
1 ^ Range resistant passage  
concentration of ^ of strains of strains  
Ciprofloxacin Ciprofloxacin 256-512 256 512 10 12 0.8 
Gemifloxacin 4 -256 16 64 53 11 4.8 
Levofloxacin 512-
1024 512 1024 5 13 0.4 
Moxifloxacin 66-256 128 128 28 11 2.5 
Norfloxacin 64-512 128 256 28 12 2.3 
Ofloxacin 256 -512 256 ^ ^ \ 2  
Gemif loxacin Ciprofloxacin 512-512 512 512 3 13 0.2 
Gemifloxacin 4 -512 16 64 15 12 1.3 
Levofloxacin 0 0 0 0 0 0 
Moxifloxacin 128-
1024 256 1024 10 13 0.8 
Norfloxacin 256 -256 256 256 2.5 12 0.2 
Ofloxacin 512-512 512 ^ ^ 13 0 2 
Levofloxacin Ciprofloxacin 128-128 128 128 2.5 12 0.2 
Gemifloxacin 8 -32 16 32 38 9 4.2 
Levofloxacin 128-128 128 128 2.5 12 0.2 
Moxifloxacin 32-64 32 64 10 11 0.9 
Norfloxacin 128-128 128 128 2.5 12 0.2 
Ofloxacin 128-128 128 12 02 
Moxifloxacin Ciprofloxacin 128-256 128 256 10 13 0.8 
Gemifloxacin 8 -128 16 64 52 11 4.8 
Levofloxacin 128-512 256 512 7.5 14 0.5 
Moxifloxacin 16-128 64 128 33 12 2.7 
Norfloxacin 128-256 128 256 20 13 1.5 
Ofloxacin 128-128 128 128 12 0.8 
Norfloxacin Ciprofloxacin 512 -512 512 512 5 13 0.4 
Gemifloxacin 4 -512 64 256 55 13 4.2 
Levofloxacin 512 -512 512 512 2.5 16 0.2 
Moxifloxacin 32-256 256 256 35 13 2.7 
Norfloxacin 128-512 256 512 25 14 1.8 
Ofloxacin 512 -512 512 ^ 5 13 ^  
Ofloxacin Ciprofloxacin 256 -256 256 256 13 13 0.9 
Gemifloxacin 4 -64 32 32 35 11 3.1 
Levofloxacin 512 -512 512 512 2.5 14 0.2 
Moxifloxacin 32 -128 64 128 20 12 1.7 
Norfloxacin 64 -256 128 256 15 13 1.2 
Ofloxacin 128-256 128 256 10 0.8 
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Table III-5. Ability of fluoroquinolones to eradicate resistant strains of Salmonella 
sp. 
Xs MIC at which resistant strains were … , 
eradicated % that were 
Selected by eraaicaiea ^ _ eradicated at 
Range 5?。/。of 9 0 % of i28mg/l  
strains strains  
Ciprofloxacin 2-4096 98 
Gemifloxacin 8-4096 32 128 100 
Levofloxacin 4-512 32 256 98 
Moxifloxacin 8-1024 128 1024 93 
Norfloxacin 8-4096 512 >4096 83 
Ofloxacin 1-1024 ^ ^ 98 
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W h e n strains were passaged in gemifloxacin or moxifloxacin, resistance 
developed per passage to the respective drugs was 4.5% and 6.5%, respectively 
which were highest among resistance that developed per passage to other 
fluoroquinolones (Table lll-6a). In contrast, the percentage of strains that 
developed resistance to levofloxacin per passage in the presence of levofloxacin 
was lowest (2.3%) as compared to that of strains that became resistant to other 
fluoroquinolones (3.7%-5.3%). 
The smallest percentage of strains developed resistance to levofloxacin in the 
presence of either of the six fluoroquinolones (3% in the presence of gemifloxacin 
- 4 3 % in the presence of ciprofloxacin) and the smallest percentage per passage 
(0.2%-3.9%). 
The concentrations of gemifloxacin and moxifloxacin at which gemifloxacin- and 
moxifloxacin-resistant strains started to appear were the lowest, being 2Xs MIC 
and 1Xs MIC, respectively, while the concentration of levofloxacin at which 
levofloxacin-resistant strains started to develop was highest, being 32Xs MIC. 
Similar results were obtained when strains developed resistance to the resistant 
breakpoint concentration of the fluoroquinolones (Table lll-6b). Resistance 
developed to gemifloxacin only when strains were passaged in gemifloxacin 
which was at a high of 4.5%. No levofloxacin-resistant strains developed in the 
presence pf moxifloxacin. Resistant strains started to appear at a low of 2Xs MIC 
of moxifloxacin to a high of 256Xs MIC of ciprofloxacin, levofloxacin or norfloxacin. 
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Table l l l -6a. Ability of fluoroquinolones to select strains of Escherichia coli resistant to sensitive breakpoint concentration of 
fluoroquinolones. 
Became resistant Xs M IC at which resistance ^ ^ . ^ 
% that % Resistance 
„ to sensitive developed , No. of , , � Selected by . . . ——7； — — ~ became developed per 
breakpoint In 5 0 % In 9 0 % . ‘ ‘ passages 
‘ ‘ Range ： ‘ . , ‘ . resistant passage  
concentration of of strains of strains  
Ciprofloxacin Ciprofloxacin 16-256 32 128 56 10 5.7 
Gemifloxacin 1 -256 16 64 68 11 6.1 
Levofloxacin 32-256 64 256 43 11 3.9 
Moxifloxacin 8 -128 16 64 59 10 5.9 
Norfloxacin 2 -256 32 64 62 10 6.2 
ofloxacin 16-128 32 64 ^ ^ 5.7 
Gemifloxacin Ciprofloxacin 64 -1024 256 1024 7.8 13 0.6 
Gemifloxacin 2 -256 16 128 50 11 4.5 
Levofloxacin 256 -256 256 256 2.6 11 0.2 
Moxifloxacin 16-1024 64 256 42 13 3.2 
Norfloxacin 2 -1024 256 1024 7.9 13 0.6 
Dfloxaein 256- 2048 16 14 1.1 
Levofloxacin Ciprofloxacin 1-64 32 64 37 10 3.7 
Gemifloxacin 0 .5-64 16 64 50 10 5.0 
Levofloxacin 32-64 64 64 24 10 2 .3 
Moxifloxacin 1-64 16 32 58 10 5.8 
Norfloxacin 1-64 32 64 50 10 5.0 
ofloxacin 4 - M ^ M 53 10 5.3 
Moxifloxacin Ciprofloxacin 1 -256 32 64 32 13 2.4 
Gemifloxacin 1-64 16 64 63 10 6.3 
Levofloxacin 16-256 64 256 18 12 1.5 
Moxifloxacin 1-64 16 32 71 11 6.5 
Norfloxacin 0 .5 -256 32 256 42 12 3.5 
ofloxacin 1 -128 32 M 48 1 j 4 .5 
Norfloxacin Ciprofloxacin 8 - 1 2 8 32 128 55 13 4 .3 
Gemifloxacin 0 .5-64 8 16 66 11 6 .0 
Levofloxacin 16-512 64 256 34 14 2.4 
Moxifloxacin 4 - 2 5 6 16 32 61 13 4.7 
Norfloxacin 8 -64 16 64 68 12 5.7 
ofloxacin 8 - 1 2 8 16 64 ^ 12 4 .8 
Ofloxacin Ciprofloxacin 4 -64 16 64 30 11 2.7 
Gemifloxacin 0 .5-64 16 32 65 11 5.9 
Levofloxacin 16-64 32 64 27 11 2.5 
Moxifloxacin 2 -32 8 32 54 10 5.4 
Norfloxacin 4 -64 32 64 46 11 4.2 
ofloxacin ^ 32 57 10 5.7 
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Table lll-6b. Ability of fluoroquinolones to select strains of Escherichia coli resistant to resistant breakpoint concentration of 
fluoroquinolones. 
Became resistant Xs M I C at which resistance 
‘ . ‘ I � ， J % that , % Resistance � • ‘ k to resistant developed ^ No. of , � Selected by . ^ became developed per 
breakpoint ^ In 5 0 % In 9 0 % passages 
, 1 . ^ Range , , resistant passage  
concentration of of strains of strains  
Ciprofloxacin Ciprofloxacin 64 -512 128 256 32 12 2.7 
Gemifloxacin 16-512 64 128 57 12 4 .7 
Levofloxacin 256-
1024 256 1024 19 13 1.5 
Moxifloxacin 64 -256 128 256 27 11 2.5 
Norfloxacin 64 -512 128 512 35 13 2.7 
Ofloxacin 6 4 - 1 0 2 4 128 ^ ^ 13 2.0 
Gemifloxacin Ciprofloxacin 0 0 0 0 0 0 
Gemifloxacin 8 -256 128 128 50 11 4.5 
Levofloxacin 0 0 0 0 0 0 
Moxifloxacin 0 0 0 0 0 0 
Norfloxacin 0 0 0 0 0 0 
Ofloxacin 0 0 0 0 0 0 
Levofloxacin Ciprofloxacin 128-128 128 128 5.2 11 0.5 
Gemifloxacin 32 -128 64 64 32 11 2.9 
Levofloxacin 2 5 6 - 2 5 6 256 256 2.6 12 0.2 
Moxifloxacin 64 -128 128 128 13 12 1.0 
Norfloxacin 64 -128 64 128 7.9 11 0.7 
Ofloxacin 64 -128 128 U 0.7 
Moxifloxacin Ciprofloxacin 32 -128 32 128 5.2 12 0.4 
Gemifloxacin 2 -64 32 64 45 11 4.0 
Levofloxacin 0 0 0 0 0 0 
Moxifloxacin 2 -256 128 256 15 12 1.3 
Norfloxacin 32-256 32 256 5.2 13 0.4 
Ofloxacin 32 -256 128 ]2 0.7 
Norfloxacin Ciprofloxacin 64 -512 128 128 29 15 1.9 
Gemifloxacin 4 -64 16 32 60 12 5.0 
Levofloxacin 256- ^ 
1024 256 1024 13 16 0.8 
Moxifloxacin 16-512 128 512 39 15 2.6 
Norfloxacin 16-512 128 128 45 15 3.0 
Ofloxacin 64 -512 128 ^ 16 1.5 
Ofloxacin Ciprofloxacin 64 -256 64 256 16 13 1.2 
Gemifloxacin 8 - 2 5 6 16 64 41 13 3.0 
Levofloxacin 64 -256 128 256 14 13 1.0 
Moxifloxacin 32 -256 32 128 24 13 1.8 
Norfloxacin 64 -512 64 512 14 14 1.0 
Ofloxacin 6 4 - 2 5 6 64 ^ ] 6 r 3 1.2 
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W h e n strains were passaged in either of the six fluoroquinolones, the largest 
proportion of strains developed resistance to gemifloxacin (32%-60%) as well as 
the largest percentage of resistant strains that developed per passage (2%-5%) 
while the smallest proportion of strains developed resistance to levofloxacin (0%-
19%) or the percentage of resistant strains per passage (0%-1.5%) 
All strains could be killed at 128 mg/l of ciprofloxacin while the smallest percentage 
was killed at 128 mg/l of norfloxacin. Strains started to be killed at 1Xs MIC of 
moxifloxacin but only at 256Xs MIC of gemifloxacin (Table 111-7). 
c. Pseudomonas aeruginosa 
W h e n strains were passaged in increasing concentration of moxifloxacin or 
ofloxacin, the largest proportion of strains developed resistance to the sensitive 
breakpoint of the respective drugs, being 9.0% and 8.4%, respectively (Table 111-
8a). The percentage of strains that became resistant to other fluoroquinolones in 
the presence of these two fluoroquinolones was 6.0%-8.3% and 6.0% and 7.7%, 
respectively. 
Ciprofloxacin could select the largest proportion of fluoroquinolone-resistant 
strains (8.4%-13% per passage) while ofloxacin selected the smallest proportion 
(6.0%-8.4% per passage). 
Fifty percent or more strains developed resistance at 2Xs - 8Xs MIC of the 
fluoroquinolones. However, in the presence of moxifloxacin, strains that were 
ciprofloxacin-resistant could only develop at 64Xs MIC of moxifloxacin. With 
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Table IH-7. Ability of fluoroquinolones to eradicate resistant strains of Escherichia 
coli. 
Xs MIC at which resistant strains were % that were 
Selected by eradicated eradicated at 
Range 5 0 % of strains 90% of strains 128 mg/l 
Ciprofloxacin 8-8192 128 2048 100 
Gemifloxacin 256-4096 512 4096 97 
Levofloxacin 0.5-2048 128 512 97 
Moxifloxacin 1-1024 128 512 97 
Norfloxacin 4-1024 128 >1024 76 
Ofloxacin 4-1024 64 ^ 97 
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Table ll l-8a. Ability of fluoroquinolones to select strains of Pseudomonas aeruginosa resistant to sensitive breakpoint 
concentration of fluoroquinolones. 
Became Xs M IC at which resistance 
resistant to developed % that N � o f % Resistance 
Selected by sensitive became developed 
^ , . 1 „ In 5 0 % of In 9 0 % of passages 
breakpoint Range resistant per passage 
• . strains strains  
concentration of  
Ciprofloxacin Ciprofloxacin 0 .25-32 4 32 93 11 8.4 
Gemifloxacin 0 .5-16 1 1 67 5 13 
Levofloxacin 2 -32 4 32 93 11 8.4 
Moxifloxacin 0.25-4 1 1 66 7 9.5 
ofloxacin 0.5-32 1 4 ^ 8 12 
Gemifloxacin Ciprofloxacin 0 .25-128 8 64 87 8 10 
Gemifloxacin 0.5-4 1 4 63 8 7.9 
Levofloxacin 1 -128 4 16 97 14 7.0 
Moxifloxacin 4 -128 8 32 60 13 4.6 
ofloxacin 1 -128 4 M 93 ^ 7.1 
Levofloxacin Ciprofloxacin 0 .12-32 4 16 73 12 6.0 
Gemifloxacin 0 .25-16 1 2 67 9 7.4 
Levofloxacin 1 -128 4 16 90 12 7.5 
Moxifloxacin 1-16 2 4 63 9 7.0 
ofloxacin ^ 2 16 83 U 7.6 
Moxifloxacin Ciprofloxacin 16-512 64 128 85 14 6.0 
Gemifloxacin 0.5-64 2 64 100 12 8.3 
Levofloxacin 8 -128 32 64 95 13 7.3 
Moxifloxacin 4 -64 8 32 100 11 9.0 
ofloxacin 8 -128 32 M 95 r 3 7.3 
Ofloxacin Ciprofloxacin 0 .12-16 1 8 73 12 6.0 
Gemifloxacin 0 .12-32 0.5 2 67 11 6.0 
Levofloxacin 1-64 2 8 93 12 7.7 
Moxifloxacin 1-8 1 2 66 10 6.6 
ofloxacin 1^16 2 8 ^ 11 8.4 
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respect to resistant breakpoint concentrations, gemifloxacin could select 
resistance to itself at 6.0% per passage while it could only select resistance to 
other fluoroquinolones at 1.0% - 4.4% per passage (Table lll-8b). At 1024Xs MIC 
of moxifloxacin or at 256Xs MIC of gemifloxacin, 5 0 % of strains became resistant 
to levofloxacin. 
Only 5 7 % of strains were killed by 128 mg/l of gemifloxacin but 9 5 % were killed 
by the same concentration of moxifloxacin (Table 111-9). Ciprofloxacin started to kill 
strains at the lowest concentration (2Xs MIC) closely followed by levofloxacin (4Xs 
MIC). Moxifloxacin only started to kill strains at 128Xs MIC while at 128Xs MIC of 
ciprofloxacin, 5 0 % were already killed. 
C. Effects of P-lactams on the development of resistance 
The same strains of the three organisms were subjected to daily passage in 
increasing two-fold dilutions of p-lactams as well as in broth containing no 
antibiotic and results interpreted as described above. 
No strain developed resistance to any of the p-lactam tested when subcultured in 
broth containing no antibiotic. 
a) Salmonella sp 
The percentage of strains resistant to sensitive breakpoint of p-lactams developed 
per passage in ceftazidime or ceftriaxone was the same and smaller than that in 
cefotaxime but no ceftriaxone-resistant strains developed when the strains were 
passaged in cefotaxime (Table lll-10a). More ceftazidime-resistant strains 
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Table lll-8b. Ability of fluoroquinolones to select strains of Pseudomonas aeruginosa resistant to resistant breakpoint 
concentration of fluoroquinolones. 
Became Xs M I C at which resistance 
resistant to developed % that N � o f % Resistance 
Selected by resistant became developed 
^ , . , „ In 5 0 % of In 9 0 % of passages 
breakpoint Range resistant per passage 
, 1 . , strains strains  conc6门tr3tion of  
Ciprofloxacin Ciprofloxacin 32 -128 32 128 43 13 3.3 
Gemifloxacin 1 -32 1 2 63 10 6.3 
Levofloxacin 32 -128 32 128 46 13 3.6 
Moxifloxacin 1 -32 1 16 53 10 5.3 
ofloxacin 16-128 16 M ^ ^ A J 
Gemifloxacin Ciprofloxacin 32 -1024 256 1024 16 16 1.0 
Gemifloxacin 0 .5 -128 1 8 67 11 6.0 
Levofloxacin 3 2 - 1 0 2 4 256 1024 26 16 1.6 
Moxifloxacin 2 - 1 2 8 8 64 57 13 4.4 
ofloxacin 16-512 64 ^ ^ ^ 4.0 
Levofloxacin Ciprofloxacin 16-256 64 128 27 14 1.9 
Gemifloxacin 0 .5-64 2 8 63 11 5.8 
Levofloxacin 8 - 2 5 6 64 128 40 14 3.0 
Moxifloxacin 2 -16 8 16 57 11 5.0 
ofloxacin 8 - 1 2 8 M M ^ H ^  
Moxifloxacin Ciprofloxacin 256 256 256 5 14 0.3 
Gemifloxacin 1-64 2 64 95 12 8.0 
Levofloxacin 1024 1024 1024 5 16 0.3 
Moxifloxacin 8 -128 32 128 95 16 5.9 
ofloxacin 128-256 128 ^ 10 H 0.7 
Ofloxacin Ciprofloxacin 16-64 16 32 26 14 1.9 
Gemifloxacin 0 .12-4 1 4 63 10 6.3 
Levofloxacin 16-32 16 16 26 13 2.0 
Moxifloxacin 2 -32 2 16 60 12 5.0 
ofloxacin 2 -64 16 64 W 14 3.8 
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Table III-9. Ability of fluoroquinolones to eradicate resistant strains of 
Pseudomonas aeruginosa. 
Xs MIC at which resistant strains were % that were 
Selected by eradicated eradicated at 
Range 5 0 % of strains 9 0 % of strains 128 mg/l 
Ciprofloxacin 2-2048 128 1024 90 
Gemifloxacin 32-1024 256 >1024 60 
Levofloxacin 4-512 125 >512 82 
Moxifloxacin 128-2048 512 1024 95 
Ofloxacin 8-256 64 >256 83 
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Table 111-1 Oa. Ability of P-lactams to select strains of Salmonella sp resistant to sensitive breakpoint concentration of p-
lactams. 
„ Xs MIC at which resistance 
Became resistant 
. .‘. developed % that . , % Resistance 
„ to sensitive No of 
Selected by , . , In 5 0 % In 9 0 % became developed per 
breakpoint passages 
concentration of Range of of resistant passage 
strains strains  
Cefotax ime Cefotaxime 16-128 32 128 15 12 1.3 
Ceftazidime 2 -128 32 128 30 13 2.3 
Ceftriaxone 0 0 0 0 0 0 
Cef taz id ime Cefotaxime 128 128 128 5 13 0.4 
Ceftazidime 16-64 32 64 10 12 0.8 
Ceftriaxone I J S 5 13 0.4 
Ceftr iaxone Cefotaxime 128 128 128 5 10 0.5 
Ceftazidime 32-32 32 32 5 8 0.6 
Ceftriaxone ^ ^ ^ 5 ^ 0.5 
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developed per passage (0.6% - 2.3%) in the presence of any of the three 
cephalosporin than strains that became resistant to the other two cepholosprins 
(0.4%-1.3。/o). 
Resistance to cefotaxime or ceftriaxone started to develop in the presence of 
128Xs MIC of ceftazidime or ceftriaxone, however, resistance to ceftazidime 
started to develop in the presence of 2Xs MIC of cefotaxime, 16Xs MIC of 
ceftazidime or 32Xs MIC of ceftriaxone. 
None of the strains became resistant to aminoglycosides in the presence of any of 
the cephalosporins. 
No strains resistant to resistant breakpoint of the three cephalosporins were 
selected by cefotaxime. Only resistance to ceftazidime emerged in the presence 
of ceftazidime at 0.8% per passage and at 32Xs MIC (Table lll-10b). No 
ceftriaxone-resistance developed in the presence of ceftriaxone but resistance to 
cefotaxime or ceftazidime developed at 0.4%-0.5% per passage and at 1024Xs 
MIC and 128Xs MIC, respectively. 
Up to 5 0 % of strains could be eradicated at 8Xs MIC of ceftazidime or ceftriaxone 
but only at 64Xs MIC of cefotaxime (Table 111-11). However, both cefotaxime and 
ceftriaxone could kill 9 5 % of strains when these drugs reached a concentration of 
128 mg/l. 
b. Escherichia coli 
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Table l l l-10b. Ability of P-lactams to select strains of Salmonella sp resistant to resistant breakpoint concentration of p-
lactams. 
r, Xs M IC at which resistance Became resistant 
, , developed % that 、， ， % Resistance 
„ , to resistant No of 
Selected by . , . . In 5 0 % In 9 0 % became developed per 
breakpoint passages 
concentration of ^ a n g e of of resistant passage 
strains strains  
Cefotax ime Cefotaxime 0 0 0 0 0 0 
Ceftazidime 0 0 0 0 0 0 
Ceftriaxone 0 0 0 0 0 0 
Ceftaz idime Cefotaxime 0 0 0 0 0 0 
Ceftazidime 32-128 32 128 10 13 0.8 
Ceftriaxone 0 0 0 0 0 Q 
Ceftr iaxone Cefotaxime 1024 1024 1024 5 13 0.4 
Ceftazidime 128 128 128 5 10 0.5 
Ceftriaxone 0 0 0 0 0 0 
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Table 111-11. Ability of (3-lactams to eradicate resistant strains of Salmonella sp 
Xs MIC at which resistant strains were  
Selected by eradicated eradicated at 
Range 5 0 % of strains 90% of strains 128 mq/l 
Cefotaxime 4-512 ^ ^ g ^ - ^  
Ceftazidime 2-512 8 32 9。 
Ceftriaxone 4-8192 8 95 
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Ceftriaxone selected the least number of strains resistant to the sensitive 
breakpoint concentration of cephalosporins (0.3%-0.6%) while ceftazidime 
selected the largest number (0.4%-2.8%) (Table 丨丨丨-12a). More strains developed 
in the presence of any of the three cephalosporins but the rate of resistance 
development was highest in the presence of ceftazidime, being 2.8% versus 1.0% 
in the presence of cefotaxime and 0.6% in the presence of ceftriaxone. However, 
resistance emerged at the MIC of ceftriaxone but at 2Xs MIC or more of 
ceftazidime or cefotaxime. 
Similar results were obtained for strains that became resistant to resistant 
breakpoints of cephalosporins except that no cefotaxime-resistant strains in the 
presence of ceftriaxone and the percentage of resistant strains that emerged were 
smaller. Resistance emerged at 4Xs MIC of ceftriaxone but at 8Xs MIC of 
cefotaxime and 16Xs MIC of ceftazidime (Table lll-12b). 
Ninety-seven percent of strains were eradicated at 128 mg/l of ceftriaxone while 
only 7 1 % were eradicated at the same concentration of ceftazidime (Table 111-13). 
Ceftriaxone also could kill 5 0 % and 9 0 % of strains at the lowest concentration of 
8Xs MIC and 32Xs MIC, respectively. 
c. Pseudomonas aeruginosa 
Ceftazidime and meropenem were the only two (3-lactams tested against P 
aeruginosa. The rate of resistance development to meropenem in the presence of 
meropenem was higher (7.8%) as compared to 5.9% that became resistant to 
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Table l l l -12a. Ability of p-lactams to select strains of Escherichia coli resistant to sensitive breakpoint concentration of 3 -
lactams. 
^ Xs MIC at which resistance 
Became resistant 
_ to sensitive ^ ^ ^ ^ % t h a t % Resistance 
Selected by breakpoint m 5 0 % 丨n • became developed per 
‘ 1. , Range of of resistant oassaae concentration of ^ jjdbbdge 
strains strains  
Cefotaxime Cefotaxime 4 -256 16 256 10 13 0.8 
Ceftazidime 0.12-64 16 64 15 15 1.0 
Ceftriaxone 0.12- …乂 __ 
1024 16 1024 13 15 0.9 
Ceftaz idime Cefotaxime 8 -512 128 512 7.9 15 0.5 
Ceftazidime 2 -256 32 64 37 13 2.8 
Ceftriaxone 2 -128 8 128 5 14 0.4 
Ceftr iaxone Cefotaxime 1-4 1 4 5.2 7 0.3 
Ceftazidime 1-4 1 4 5.2 9 0.6 
Ceftriaxone 1-4 1 4 ^ 9 0.6 
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Table 111-12b. Ability of P-lactams to select strains of Escherichia coli resistant to resistant breakpoint concentration of (3-
lactams. 
„ Xs M IC at which resistance 
Became resistant 
, . . . developed % that % Resistance 
… � L to resistant No of 
Selected by . , . . In 5 0 % In 90% became developed per 
breakpoint passages ^ ^ 
‘ ‘. . Range of of resistant passage 
concentration of ^ ^  
strains strains  
Cefotax ime Cefotaxime 512-
1024 512 1024 5 15 0.3 
Ceftazidime 8 -1024 256 1024 10 15 0.7 
Ceftriaxone 512 -512 512 512 ^ ^ 0.2 
Ceftaz idime Cefotaxime 256 -512 256 512 5.2 15 0.4 
Ceftazidime 16-128 64 128 16 14 1.1 
Ceftriaxone 128-256 128 256 ^ W 0.4 
Ceftr iaxone Cefotaxime 0 0 0 0 0 0 
Ceftazidime 4 -256 4 256 5.2 15 0.4 
Ceftriaxone 256 -256 256 ^ 15 0.4 
58 
Table 111-13. Ability of p-lactams to eradicate resistant strains of Escherichia coli. 
Xs MIC at which resistant strains were % that w e r e ~ 
Selected by eradicated eradicated at 
Range 5 0 % of strains 9 0 % of strains 128 mg/l 
Cefotaxime 1-2048 64 2048 90 
Ceftazidime 2-256 32 >256 71 
Ceftriaxone 1-512 8 ^ 97 
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ceftazidime in the presence of ceftazidime (Table lll-14a). Resistance to 
meropenem also emerged at a lower concentration (2Xs MIC of meropenem) than 
resistance to ceftazidime (16Xs MIC of ceftazidime) 
Similar results as for sensitive breakpoints were obtained when strains were 
tested for resistance to resistant breakpoint of the cephalosporins except rates of 
resistance development were lower and no meropenem-resistant strains emerged 
in the presence of ceftazidime (Table lll-14b). 
Only 4 0 % of strains were eradicated at 128 mg/l of meropenem as compared to 
6 0 % at 128 mg/l of ceftazidime (Table 111-15). Meropenem started to kill strains at 
higher concentrations than ceftazidime (32Xs MIC vs 0.5Xs MIC) and 50% of 
strains could only be killed at 128XS MIC of meropenem but at 32Xs MIC of 
ceftazidime. 
D. Effects of aminoglycosides on the development of resistance 
The same strains of the three organisms were passaged daily in increasing two-
fold dilutions of aminoglycosides and results interpreted as described above. No 
resistant strains developed when they were subcultured in broth containing no 
antibiotic. 
a. Salmonella sp 
The percentage of strains that became resistant to netilmicin in the presence of 
netilmicin was lowest (1.5%) and the percentage that became resistant to 
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Table l l l -14a. Ability of p-lactams to select strains of Pseudomonas aeruginosa resistant to sensitive breakpoint 
concentration of P-lactams. 
- Xs M IC at which resistance 
Became resistant 
c , _ to sensitive ^ ^ ^ ^ ^ % Resistance 
Selected by . . . , In 5 0 % In 90% became developed oer breakpoint passages p 口 
concentration of Range of of resistant passage 
strains strains  
Ceftazidime Ceftazidime 0 .5 -128 16 32 83 14 5.9 
Meropenem 8 -16 8 ^ 17 14 1.2 
M e r o p e n e m Ceftazidime 1 -256 32 128 63 15 4.2 
Meropenem 0.5-32 2 16 93 12 7.8 
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Table l l l -14b. Ability of P- lactams to select strains of Pseudomonas aeruginosa resistant to resistant breakpoint 
concentration of P- lactams. 
B e c a m e resistant to X s M I C at which resistance developed % that ‘， ^ % Resistance 
No of 
Selected by resistant breakpoint In 5 0 % of In 9 0 % of became developed per 
‘ Range . , . passages  conc6门tr3tion of strains strains resistant passage 
Ceftaz idime Cef taz id ime 1 -256 8 32 57 15 3.7 
M e r o p e n e m 0 0 0 0 0 0 
M e r o p e n e m Cef taz id ime 16 -128 32 128 20 14 1.4 
M e r o p e n e m 2 - 5 1 2 32 §7 16 4.1 
62 
Table 111-15. Ability of (3-lactams to eradicate resistant strains of Pseudomonas 
aeruginosa. 
Xs MIC at which resistant strains were % that were 
Selected by eradicated eradicated at 
Range 5 0 % of strains 90% of strains 128 mg/l 
Ceftazidime 0.5-128 64 >128 60 
Meropenem 32-512 >512 40 
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gentamicin in the presence of gentamicin was highest (8.0%) (Table 丨丨丨-16a). 
More gentamicin resistant strains developed in the presence of amikacin than 
amikacin- resistant strains (5.8% vs 4.6%). The least number of netilmicin-
resistant strains developed in the presence of any of the three aminoglycosides 
(1.5%-1.9%). Fifty percent of strains developed resistance to netilmicin only when 
the concentration of the selecting drug reached 16Xs MIC but only 2Xs-4Xs MIC 
for strains that became gentamicin- or amikacin-resistant. 
None of the strains became resistant to cephalosporins in the presence of any of 
the aminoglycosides. 
Gentamicin could only select resistance to itself but not to amikacin or netilmicin 
since no strains became resistant to breakpoint concentration of these two 
aminoglycosides in the presence of gentamicin (Table lll-16b). Amikacin could 
select resistance to gentamicin or netilmicin at 1.5% per passage but to itself at 
0.2% only. Netilmicin could select more gentamicin-resistant strains than 
amikacin- or netilmicin- resistant strains (2.0% vs 0.6%). Resistance to netilmicin 
developed latest in the presence of amikacin (at 16Xs MIC) and resistance to 
amikacin developed latest in the presence of netilmicin (at 64Xs MIC). 
Only 1 5 % of strains were eradicated when amikacin concentration reached 128 
mg/l while 7 0 % were eradicated by 128 mg/l of gentamicin or netilmicin (Table III-
17). All three aminoglycosides started to eradicate strains at 2Xs MIC and by 
16Xs MIC, 9 0 % of strains were killed. 
64 
Table l l l -16a. Ability of aminoglycosides to select strains of Salmonella sp resistant to sensitive breakpoint concentration of 
aminoglycosides. 
Xs MIC at which resistance 
Became resistant , i … „, „ . 
developed % that " , % Resistance 
to sensitive — No of 
Selected by In 5 0 % In 9 0 % became developed per 
breakpoint , , . … passages 
, Range of of resistant passage 
concentration of 
strains strains  
Amikacin Amikacin 0.5-4 4 4 60 13 4 .6 
Gentamicin 0.25-4 0.5 2 75 13 5.8 
Netilmicin ^ 16 32 ^ 16 1.9 
Gentamicin Amikacin 0.5-16 2 8 50 12 4.0 
Gentamicin 1-4 2 4 80 10 8.0 
Netilmicin 8-32 16 32 ^ 13 1.5 
Netilmicin Amikacin 1 -128 2 8 90 15 6.0 
Gentamicin 1-4 2 4 95 10 9.5 
Netilmicin 16-32 16 ^ ^ 13 1.5 
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Table ll l-16b. Ability of aminoglycosides to select strains of Salmonella sp resistant to resistant breakpoint concentration of 
aminoglycosides. 
Xs MIC at which resistance 
Became resistant � , � o, „, ^ . , 
developed % that , % Resistance 
to resistant — , No of 
Selected by In 50% In 9 0 % became developed per 
breakpoint , , . … passages 
‘ . , Range of of resistant passage 
concentration of 
strains strains  
Amikacin Amikacin 2-32 4 32 30 16 0.2 
Gentamicin 2 -32 4 32 25 16 1.5 
Netilmicin 16-32 32 ^ ^ 16 1.5 
Gentamicin Amikacin 0 0 0 0 0 0 
Gentamicin 2 -32 4 32 25 13 1.9 
Netilmicin 0 0 0 0 0 0 
Netilmicin Amikacin 64 -256 64 256 10 16 0.6 
Gentamicin 1-256 4 16 35 16 2.0 
Netilmicin 2 -128 16 ^ 10 ] 5 0.6 
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Table 111-17. Ability of aminoglycosides to eradicate resistant strains of Salmonella 
sp. 
Xs MIC at which resistant strains were u^ ‘ 
eradicated % that were 
Selected by ^ 5 0 ^ 9 0 % of at 
strains strains 128 mg/l 
Amikacin 2-16 >16 >16 15 
Gentamicin 2-32 16 >32 70 
Netilmicin 2-128 8 > 1 ^ 75 
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b. Escherichia coli 
Gentamicin could select the largest proportion of strains resistant to the sensitive 
breakpoint concentration of gentamicin (7.9% per passage) than amikacin (3.8% 
per passage) or netilmicin (2.6% per passage) (Table lll-18a). More strains 
become resistant to gentamicin in the presence of any of the aminoglycosides 
(6.0%-7.9% per passage) as compared to those that became resistant to 
netilmicin (1.8% - 2.6% per passage) and amikacin (3.8% - 5.2% per passage). 
Besides, gentamicin-resistance developed earliest and by 2Xs MIC of any of the 
aminoglycosides, 5 0 % had already become gentamicin-resistant while netilmicin-
resistance developed latest and 5 0 % of strain became resistant to netilmicin only 
at 16Xs MIC of any of the three aminoglycosides. 
Similar results were obtained for strains that developed resistance to the resistant 
breakpoint concentration of the aminoglycosides except that less strains 
developed resistance per passage (0.5% - 4.8%) (Table lll-18b). Less than 8 0 % 
of strains were killed at 128 mg/l of amikacin or netilmicin but 8 4 % were killed by 
128 mg/l of gentamicin (Table 111-19). Amikacin and gentamicin started to kill 
strains at 2Xs MIC but netilmicin could only do so at 8Xs MIC. 
c. Pseudomonas aeruginosa 
All three aminoglycosides could select similar proportion of resistant strains of P 
aeruginosa, 6 % per passage in netilmicin and 6.7% per passage in amikacin or 
gentamicin (Table lll-20a). By 2Xs- 4Xs MIC, 5 0 % of strains had developed 
resistance to the sensitive breakpoint of the aminoglycosides. 
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Table 111-18a. Ability of aminoglycosides to select strains of Escherichia coli resistant to sensitive breakpoint concentration 
of aminoglycosides. 
„ Xs MIC at which resistance 
Became resistant , … „, 
developed % that , , , % Resistance 
… . to sensitive ； , No of , , 
Selected by . , . In 50% In 90% became developed per 
breakpoint passages 
, Range of of resistant passage 
concentration of 
strains strains  
Amikacin Amikacin 0.5-64 4 8 62 16 3.8 
Gentamicin 0.25-32 2 4 87 14 6.2 
Netilmicin 2 - M 16 32 28 16 1.8 
Gentamicin Amikacin 1-128 4 8 79 16 5.0 
Gentamicin 1-8 2 8 95 12 7.9 
Netilmicin 4 -32 16 32 28 ] 3 2.2 
Netilmicin Amikacin 2 -512 4 16 85 16 5.2 
Gentamicin 0 .5-256 2 4 97 16 6.0 
Netilmicin 16 32 33 13 2.6 
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Table ll l-18b. Ability of aminoglycosides to select strains of Escherichia coli resistant to resistant breakpoint concentration 
of aminoglycosides. 
Xs MIC at which resistance 
Became resistant � ， � … … „ . 
developed % that % Resistance 
to resistant — No of 
Selected by In 50% In 9 0 % became developed per 
breakpoint , , . ^ , passages 
, Range of of resistant passage 
concentration of ^ . 
strains strains  
Amikacin Amikacin 2 -32 4 8 48 15 3.2 
Gentamicin 1-16 8 16 59 15 3.9 
Netilmicin 32-128 64 ^ 16 0.5 
Gentamicin Amikacin 1-32 4 8 28 13 2.1 
Gentamicin 1-16 4 8 51 12 4.2 
Netilmicin 16-64 32 64 T G 14 0.5 
Netilmicin Amikacin 2 -256 4 16 49 16 3.0 
Gentamicin 1-512 4 16 77 16 4.8 
Netilmicin 4 -128 32 64 18 14 1.3 
70 
Table 111-19. Ability of aminoglycosides to eradicate resistant strains of 
Escherichia coli. 
Xs MIC at which resistant strains were 0/ …一 
. . % that were 
Selected by ^ I Z T T eradicated at 
D 5 0 % of 9 0 % of .OQ rr.r.l\  
Range strains strains 128mg/丨 
Amikacin 2-128 16 >128 72 
Gentamicin 2-512 32 >512 84 
Netilmicin 8-512 32 > 5 U 77 
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Table l l l -20a. Ability of aminoglycosides to select strains of Pseudomonas aeruginosa resistant to sensitive breakpoint 
concentration of aminoglycosides. 
Xs MIC at which resistance 
Became resistant , , , 
developed % that , , , % Resistance 
to sensitive No of 
Selected by In 5 0 % In 90% became developed per 
breakpoint , . ^ , passages 
, Range of of resistant passage 
concentration of 
strains strains  
Amikacin Amikacin 1-64 4 16 100 15 6.7 
Gentamicin 0.5-64 4 8 96 14 6.9 
Netilmicin 0.12-64 4 32 % 14 6.9 
Gentamicin Amikacin 0.5-32 4 16 77 13 5.8 
Gentamicin 0.5-32 4 16 80 12 6.7 
Netilmicin 0.12-32 4 16 72 13 5.6 
Netilmicin Amikacin 0.5-16 2 8 83 14 5.9 
Gentamicin 0 .25-16 1 4 90 15 6.0 
Netilmicin 1^32 2 8 W 13 6.4 
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Similar results were obtained for strains that developed resistance to breakpoints 
for resistant strains: 5.0% per passage in netilmicin, 6.0% in amikacin and 6.4% in 
gentamicin (Table lll-20b). Resistance to gentamicin emerged most rapidly since 
by 4Xs MIC of any of the three aminoglycosides, 5 0 % of strains had already 
become resistant to gentamicin. 
Only 3 0 % of strains were eradicated when amikacin or netilmicin concentration 
reached 128 mg/l but 6 3 % were eradicated by gentamicin at the same 
concentration (Table 111-21). Both gentamicin and netilmicin started to eradicate 
strains at low concentrations. 
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Table lll-20b. Ability of aminoglycosides to select strains of Pseudomonas aeruginosa resistant to resistant breakpoint 
concentration of aminoglycosides. 
Xs MIC at which resistance 
Became resistant ^ .. , „ . , 
developed % that , % Resistance 
to resistant “ — No of 
Selected by In 50% In 90% became developed per 
breakpoint _  , . , , passages 
, Range of of resistant passage 
concentration of � . strains strains  
Amikacin Amikacin 4 - 6 4 16 32 90 15 6.0 
Gentamicin 0 .25-64 4 32 96 14 6.9 
Netilmicin 2 -128 32 M 70 16 4.3 
Gentamicin Amikacin 2 -64 8 32 70 13 5.3 
Gentamicin 0 .5-32 4 16 83 13 6.4 
Netilmicin 4 -128 16 64 ^ 13 4.6 
Netilmicin Amikacin 1 -128 8 16 80 16 5.0 
Gentamicin 0 .25-16 4 8 83 14 6.0 
Netilmicin 2 -128 8 ^ 77 15 5.0 
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Table 111-21. Ability of aminoglycosides to eradicate resistant strains of 
Pseudomonas aeruginosa. 
Xs MIC at which resistant strains were 0/ .u^t 
, , % that were 
selected by — ^ f ^ f ^ g O S ^ 
Range strains strains ^28 mg/j 
Amikacin 4-128 ^ ^ ^ 
Gentamicin 0.25-256 64 >256 63 
Netilmicin 0.5-64 ^ ^ 30 
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Chapter 4 Discussion 
Traditionally, the method of accessing the suitability of an antimicrobial agent to 
be used in a clinical condition is to test the susceptibility of the offending organism. 
Previous studies have shown that antimicrobial susceptibility of an organism is not 
the sole factor to consider in a therapeutic regime (Chan etal., 1999). It is equally 
important to note the potential of a drug to select resistant mutants as well as the 
speed with which organisms develop resistance to it and the proportion of 
organisms that became resistant after being exposed to it. It is, therefore, 
important to determine not only the MIC of the drug but also the frequency with 
which bacteria mutate to become resistant to the drug (Fuchs et al., 1993). 
In the present study, w e have made several interesting observations on these 
aspects of six fluoroquinolones, four (3-lactams and three aminoglycosides with 
regards to three common bacterial pathogens, namely, Salmonella sp, E coli and 
P aeruginosa. 
Firstly, the ability to select for resistance varies among members of the same 
class of antibiotics. This could be seen from the percentage of strains that 
developed resistance to a drug per passage in antibiotic-containing broth. A low 
percentage indicates that resistant strains appear very slowly since it takes longer, 
ie more passages, for them to develop resistance than those strains which have a 
high percentage. 
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The concentration of a drug at which resistant strains started to develop was 
taken and compared to the MICs of that drug to these strains. This comparison is 
necessary since the concentration will be higher if the MIC is higher. Thus, a drug 
that inhibits strains only at high concentrations will select resistance at high 
concentrations too and the reverse is true. The calculated value is expressed as 
the number of times the concentration is higherthan the MIC, Xs MIC. The lower 
the Xs MIC, the faster resistance will develop since concentration of a drug that is 
slightly higher than the MIC for a strain will select resistant progenies. On the 
contrary, a high Xs MIC value indicates that the concentration of a drug has to 
reach to a high value than that required to inhibit the strains before resistant 
strains develop so that resistance develops much slower. The Xs MIC at which 
5 0 % of strains develop resistance and that at which 9 0 % of strains develop 
resistance are also indications of the speed at which a drug selects resistance in 
a population of strains. 
Our results showed that the fluoroquinolones tested had different potentials to 
select resistant strains of Salmonella sp, E coli and P aeruginosa. Gemifloxacin 
and moxifloxacin had the highest potential to select Salmonella and E coli strains 
resistant to these two fluoroquinolones while levofloxacin had the lowest potential. 
Moxifloxacin had the highest potential to select resistant strains of P aeruginosa. 
However, gemifloxacin was not able to select E coli strains resistant to resistant 
breakpoints of any of the fluoroquinolomes other than gemifloxacin while it most 
readily selected gemifloxacin-resistant P aeruginosa but not strains resistant to 
other fluoroquinolones. O n the whole, less strains developed resistance to the 
resistant breakpoint concentration of all the fluoroquinolones tested. 
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Resistance to gemifloxacin also developed most readily if Salmonella strains were 
passaged in any of the six fluoroquinolones while resistance to ciprofloxacin or 
levofloxacin developed least readily in terms of the concentration at which strains 
developed resistance and the percentage of strains that developed resistance. 
Levofloxacin-resistant E coli also developed least readily. 
Resistance to resistant breakpoint of levofloxacin did not develop readily in E coli 
strains if they were passaged in moxifloxacin or gemifloxacin. 
Boos et al (2001) also tested the ability of quinolones to select resistance, albeit in 
three Gram-positive bacteria {Streptococcus pneumoniae, Streptococcus 
pyogenes and Staplylcoccus aureus). They found that resistance developed to all 
the quinolones tested although they had similar potentials to select for resistance. 
Whether this was due to difference in the organisms tested as compared to ours 
remains to be determined. 
Gilbert and colleages (2001) demonstrated that the three fluoroquinolones they 
tested, namely ciprofloxacin, levofloxacin and trovaloxacin selected resistant E 
coli strains at different frequencies as shown in our study. Although w e did not 
test trovafloxacin, their studies showed that both levofloxacin and ciprofloxacin 
less readily select for resistance than trovafloxacin. 
Although gemifloxacin was able to kill all strains of Salmonella sp tested at 128 
mg/l, ofloxacin started to kill strains at the lowest Xs MIC. E coli strains could only 
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be killed at high concentrations of gemifloxacin. As for Salmonella sp, E coli could 
be killed at low concentrations of ofloxacin. Norfloxacin killed the smallest number 
of strains at 128 mg/l. In contrast, the least number of strains of P aeruginosa 
were killed at 128 mg/l of gemifloxacin while moxifloxacin killed the largest 
number of strains at the same concentration. Both ciprofloxacin and levofloxacin 
were able to kill these strains at low concentrations. 
As for fluoroquinolones, the three cephalosporins tested showed different abilities 
to select resistant strains of salmonellae and E coli. The rates of resistance 
development of Salmonella to sensitive breakpoint of cephalosporins in the 
presence of ceftazidime and ceftriaxone were similar but lower than those for 
cefotaxime while the rate of resistance development of E coli in the presence of 
ceftriaxone was lowest despite resistance appeared sooner. More salmonellae 
developed resistance to ceftazidime in the presence of any of the three 
cephalosporins and at the lowest concentrations. 
Salmonellae that became resistant to resistant breakpoint concentration of 
ceftazidime developed in the presence of ceftazidime or ceftriaxone but not 
cefotaxime. Similarly, ceftazidime could only select resistance to itself but not the 
other two cephalosporins. In contrast, ceftriaxone could select resistance to 
cefotaxime or ceftazidime bot not to itself and resistance only emerged at high 
concentrations (128Xs MIC). Thus, cefotaxime seemed least readily to select 
cephalosporin-resistant salmonellae and resistance to it least readily developed. 
E coli strains resistant to resistant breakpoint of ceftazidime also developed more 
readily than resistance to the other two cephalosprins. 
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Only two 3 -lactams, ceftazidime and meropenem were tsted for P aeruginosa. 
Meropenem could select for meropenem-resistant strains more readily than 
ceftazidime to select ceftazidime-resistant strains and also at lower 
concentrations. This is in contrast to that observed by Carsenti-Etesse and 
colleagues (2001) who found that imipenem, anothercarbapenem, selected the 
least number of resistant strains than the cephalosporins that they tested which 
included ceftazidime. Whether this is due to the difference of meropenem and 
imipenem in selecting for resistance requires to be examined. 
The three cephalosporins had different bactericidal effect on salmonellae and E 
coli. While ceftazidime and ceftriaxone were comparable in their ability to kill 
resistant salmonellae, ceftriaxone was most efficient in killing resistant E coli 
strains. 
Ceftazidime more readily kill resistant strains of P aeruginosa than meropenem 
since a lower concentration could achieve this and more strains were killed. 
Davies et al (1999) were unable to select S pneumoniae strains resistant to 
amoxicillin-clavulanic acid in the presence of this drug concentration. Although 
Clark and colleagues (2002) could select amoxicillin-clavulanic acid-resistant 
Haemophilus influenzae strains in the presence of the drug combination, the 
increase in MIC was low. It would be interesting to test this combination on our 
selection of Salmonella and E coli. 
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Three aminoglycosides were tested on all three organisms and their ability to 
select for resistance varied. While netilmicin-resistant salmonellae developed 
least readily in the presence of any of the aminoglycosides, netilmicin was most 
efficient in selecting resistant strains especially those resistant to gentamicin. In 
contrast, netilmicin was least efficient in selecting for resistant E coli and all three 
aminoglycosides had similar potential to select for resistant P aeruginosa strains. 
Aminoglycoside-resistant P aeruginosa also developed at low concentration of the 
selecting drugs. This could explain why aminoglycoside-resistant P aeruginosa 
strains were not uncommon. 
Resistance to the resistant breakpoint of amikacin developed least readily in 
salmonellae in the presence of any of the three aminoglycosides while that of 
gentamicin developed most readily. This probably explained why amikacin-
resistance was still uncommon after amikacin has been in clinical use for many 
years and gentamicin-resistance was prevalent. 
All three aminoglycosides had similar efficiencies to kill resistant strains of 
Salmonella sp, E coli or P aeruginosa since these drugs started to kill strains at 
low concentrations. 
To summarize, both ciprofloxacin and levofloxacin most readily selected 
fluoroquinolone-resistance, but resistance to them was the last to develop in the 
presence of any of the six fluoroquinolones tested. However, a considerably large 
proportion of strains were selected by ciprofloxacin. These two fluoroquinolones 
were also good in eradicating resistant mutants. O n the other hand, gemifloxacin, 
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moxifloxacin and norfloxacin least readily selected fluoroquinolone-resistance, but 
resistance to them was the first to develop in the presence of any of the six 
fluoroquinolones tested. However, a large proportion of strains were selected and 
they were also not efficient in eradicating resistant mutants. 
In general, ceftazidime least readily selected resistance although resistance to it 
readily developed in the presence of a p-lactam drug. Amikacin was the best of 
the aminoglycosides tested in being least ready to select for resistance and 
resistance to it developed least readily. 
Areas for future research 
Results of this study have revealed interesting features of different antimicrobial 
agents in terms of their capabilities to select and kill resistant mutants and the rate 
at which organisms developed resistance to them. It has also opened many 
opportunities for further work to be done. 
1 • Resistance mechanisms of resistant mutants that developed at different stages 
of selection by antimicrobial agents - By unraveling the sequential development 
of resistance mechanisms in the presence of different antimicrobial agents, new 
drugs can be designed to overcome these mechanisms so that they can be less 
efficient in selecting for resistance as well as in delaying the development of 
resistant bacteria. 
2. Optimization of procedures in the investigation of the selective capabilities of 
antimicrobial agents - Although this study has produced several interesting 
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findings, the procedures involved are tedious and labour intensive and are not 
suitable for large-scale investigation. The methods can be refined and optimized 
so that such parameters of new drugs and on other bacterial species can be 
investigated more efficiently. 
3. Development of resistance in different Salmonella serotypes 一 Due to time 
constraint, w e did not test a substantial number of strains of each of the major 
Salmonella serotypes found in Hong Kong. It would be interesting to find out 
whether different Salmonella serotypes behaved differently in the presence of 
antimicrobial agents in terms of development of resistance. ResuKs obtained 
might be used to explain why Salmonella serotype Typimurium is usually more 
antibiotic-resistant than other Salmonella serotypes. 
4. Stability of resistance - Another important aspect of antibiotic resistance is 
whether the resistance that developed in a strain can be stably maintained. This 
could be done by subjecting resistant mutants to daily subculture in antibiotic-free 
broth over a period of time and then test the susceptibility of the daughter cells 
daily. That resistance that remained after many generations would pose a much 
greater problem clinically than those that disappeared soon after development. 
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